Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	May 12	EXTEND option available in structure searching
NEWS 4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS 5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS 6	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS 7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS 8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS 9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS 10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS 11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS 12	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS 13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS 14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS 15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:45:12 ON 20 AUG 2004

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:45:22 ON 20 AUG 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 AUG 2004 HIGHEST RN 728239-10-9
DICTIONARY FILE UPDATES: 18 AUG 2004 HIGHEST RN 728239-10-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10049288.str





chain nodes :
6 8 9 10 12 13
ring nodes :
1 2 3 4 5
ring/chain nodes :
7 11
chain bonds :
1-6 2-7 3-8 4-9 9-10 9-12 10-11 10-13
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 4-9 9-10 10-11 10-13
exact bonds :
1-6 2-7 3-8 9-12

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 10:45:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 95 TO ITERATE

100.0% PROCESSED 95 ITERATIONS 19 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1316 TO 2484
PROJECTED ANSWERS: 119 TO 641

L2 19 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 10:45:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1800 TO ITERATE

100.0% PROCESSED 1800 ITERATIONS 371 ANSWERS
SEARCH TIME: 00.00.01

L3 371 SEA SSS FUL L1

=> s l3 and caplus/lc
38032970 CAPLUS/LC
L4 359 L3 AND CAPLUS/LC

=> s l3 not l4
L5 12 L3 NOT L4

=> d l5 1-12

L5 ANSWER 1 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 705269-97-2 REGISTRY
CN Benzamide, 4-fluoro-N-[[(5-methyl-1H-pyrazol-3-yl)amino]carbonyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C12 H11 F N4 O2
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 2 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 705269-94-9 REGISTRY
CN Benzamide, N-[[(5-methyl-1H-pyrazol-3-yl)amino]carbonyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C12 H12 N4 O2
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 3 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 497161-16-7 REGISTRY
CN Benzamide, N-[[(5-methyl-1H-pyrazol-3-yl)amino]carbonyl]-3-(1,1,2,2-tetrafluoroethoxy)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C14 H12 F4 N4 O3
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 4 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 497161-15-6 REGISTRY
CN Benzamide, 2-fluoro-N-[[(5-methyl-1H-pyrazol-3-yl)amino]carbonyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C12 H11 F N4 O2
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 5 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 497161-14-5 REGISTRY
CN Benzamide, 2,4-difluoro-N-[[(5-methyl-1H-pyrazol-3-yl)amino]carbonyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C12 H10 F2 N4 O2
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 6 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 497154-63-9 REGISTRY
CN Benzamide, N-[[(5-methyl-1H-pyrazol-3-yl)amino]carbonyl]-4- (trifluoromethyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H11 F3 N4 O2
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 7 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 497154-62-8 REGISTRY
CN Benzamide, 3-chloro-N-[[(5-methyl-1H-pyrazol-3-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C12 H11 Cl N4 O2
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 8 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 392708-05-3 REGISTRY
CN Urea, N,N''-1,6-hexanediylbis[N'-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H30 N8 O2
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 9 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 366492-53-7 REGISTRY
CN Urea, N-[1-methyl-1-[3-(1-methylethenyl)phenyl]ethyl]-N'-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H22 N4 O
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 10 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 256529-50-7 REGISTRY
CN Urea, N-ethyl-N'-[5-[4-phenyl-5-(trifluoromethyl)-2-thienyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H15 F3 N4 O S
SR CAS Client Services



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 11 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 256525-82-3 REGISTRY
CN Urea, N-(4-chlorophenyl)-N'-[5-[4-phenyl-5-(trifluoromethyl)-2-thienyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H14 Cl F3 N4 O S
SR CAS Client Services



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 12 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 229001-88-1 REGISTRY
CN Benzamide, 3-[4-[[[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H25 N5 O3
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   181.09     181.30

FILE 'CAPLUS' ENTERED AT 10:46:07 ON 20 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 20 Aug 2004  VOL 141 ISS 8
FILE LAST UPDATED: 18 Aug 2004  (20040818/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> d his

     (FILE 'HOME' ENTERED AT 10:45:12 ON 20 AUG 2004)

     FILE 'REGISTRY' ENTERED AT 10:45:22 ON 20 AUG 2004
L1             STRUCTURE UPLOADED
L2          19 S L1
L3         371 S L1 FULL
L4         359 S L3 AND CAPLUS/LC
L5          12 S L3 NOT L4

     FILE 'CAPLUS' ENTERED AT 10:46:07 ON 20 AUG 2004

=> s l4
L6          38 L4

=> d ibib abs hitstr 1-38
```

L6 ANSWER 1 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:369129 CAPLUS
DOCUMENT NUMBER: 141:81627
TITLE: SDOCKER: A Method Utilizing Existing X-ray Structures To Improve Docking Accuracy
AUTHOR(S): Wu, Guosheng; Vieth, Michal
CORPORATE SOURCE: Lilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 46285, USA
SOURCE: Journal of Medicinal Chemistry (2004), 47(12), 3142-3148
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB This paper introduces a new strategy for structure-based drug design that combines high-quality docking with data from existing ligand-protein cocrystal x-ray structures. The main goal of SDOCKER, a new algorithm that implements this strategy, is docking accuracy improvement. In this new paradigm, simulated annealing mol. dynamics is used for conformational sampling and optimization and an addnl. similarity force is applied on the basis of the positions of ligands from x-ray data that focus the sampling on relevant regions of the active site. Because the structural information from both the ligand and protein active site is included, this approach is more effective in finding the optimal conformation for a ligand-protein complex than the classical docking or similarity overlays. Interestingly, it was found that a 3D similarity-only approach gives comparable docking accuracy to the regular force field approach used in classical docking, given the final structures are minimized in the presence of the protein. The combination of both, as implemented in SDOCKER, is shown here to be more accurate. A significant improvement in docking accuracy has been observed for three different test systems. Specifically an improvement of 10%, 17.5%, and 10% is seen for 37 HIV-1 protease, 32 thrombin, and 23 CDK2 ligands, resp., compared to docking using the force field alone. In addition, SDOCKER's accuracy performance dependence on the similarity template is discussed. The strategy of utilizing existing ligand x-ray information should prove effective in light of the multitude of structures available from structural genomics approaches.

IT **360068-25-3**
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SDOCKER is method utilizing existing x-ray structures to improve docking accuracy)

RN 360068-25-3 CAPLUS
CN Urea, N-[5-(2-pyrrolidinyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:220307 CAPLUS
DOCUMENT NUMBER: 140:270555
TITLE: Preparation of diarylurea derivatives and their use as chloride channel blockers
INVENTOR(S): Dahl, Bjarne H.; Christophersen, Palle; Engsig, Michael Thyrring; Karsdal, Morten Asser; Foged, Niels Taekker; Jensen, Flemming Reissig
PATENT ASSIGNEE(S): Neurosearch A/s, Den.
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022529	A2	20040318	WO 2003-DK575	20030904
WO 2004022529	A3	20040513		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: DK 2002-1306 A 20020905
DK 2002-1310 A 20020905

OTHER SOURCE(S): MARPAT 140:270555
GI



I

AB ANHCONR1D [A = (un)substituted cyclohexyl, Ph, pyridyl, thienyl, naphthyl, indolyl, pyrazolyl, oxopyrrolidinyl; R1 = H, D = (un)substituted Ph, cyclohexyl, 2-pyridinyl, CHR2CO2H; R2 = (un)substituted Ph; R1D = CH(CO2H)CH2CHR3CH2; R3 = H, OH] were prepared for use as chloride channel blockers in the treatment of bone metabolic diseases, diseases responsive to modulation of the mast cell or basophil activity, diseases responsive to inhibition of angiogenesis, or sickle cell anemia (no data). Thus, 4-BrC6H4Me was converted to 4-MeC6H4B(OH)2, which was oxidized to 4-HO2CC6H4B(OH)2 and amidated to 4-Me2NCOC6H4B(OH)2. Coupling with 5,2-Br(H2N)C6H3CN gave 4,3-H2N(NC)C6H3C6H4CONMe2-4 which was cyclized to the tetrazole and treated with 3,5-(F3C)2C6H3NCO to give the urea I.

IT **674300-18-6P**

L6 ANSWER 2 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of diarylurea derivs. and their use as chloride channel blockers)

RN 674300-18-6 CAPLUS
CN Benzoic acid, 4-chloro-2-[[[(5-phenyl-1H-pyrazol-3-yl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



L6 ANSWER 3 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:182368 CAPLUS
DOCUMENT NUMBER: 140:229401
TITLE: Three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands
INVENTOR(S): Come, Jon H.; Becker, Frank; Kley, Nikolai A.; Reichel, Christoph
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 238 pp., Cont.-in-part of U.S. Ser. No. 91,177.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004043388	A1	20040304	US 2002-234985		20020903
US 2003165873	A1	20030904	US 2002-91177		20020304
PRIORITY APPLN. INFO.:			US 2001-272932P	P	20010302
			US 2001-278233P	P	20010323
			US 2001-329437P	P	20011015
			US 2002-91177	A2	20020304

AB The invention provides compns. and methods for isolating ligand-binding polypeptides for a user-specified ligand, and for isolating small mol. ligands for a user-specified target polypeptide using an improved class of hybrid ligand compds. Preparation of compds., e.g a methotrexate moiety linked
by a polyethylene gycol moiety to dexamethasone, is described.
IT **322689-01-0D**, conjugates **322689-07-6D**, conjugates
666838-82-0D, conjugates
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
RN 322689-01-0 CAPLUS
CN Urea, N-[5-[[[(2S)-5-chloro-2,3-dihydro-1H-inden-2-yl]amino]methyl]-1H-pyrazol-3-yl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 3 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-07-6 CAPLUS
CN Urea, N-[5-[[[(2S)-5-chloro-2,3-dihydro-1H-inden-2-yl]amino]methyl]-1H-pyrazol-3-yl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 666838-82-0 CAPLUS
CN Urea, N-[5-[[(1,1-dimethylethyl)amino]methyl]-1H-pyrazol-3-yl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 3 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L6 ANSWER 4 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:80448 CAPLUS
DOCUMENT NUMBER: 140:122817
TITLE: NPY5 antagonist-antiobesity agent combination for the prevention and treatment of diabetes, obesity, and obesity-related disorders
INVENTOR(S): Macneil, Douglas J.; McIntyre, James H.; Van Der Ploeg, Leonardus H. T.; Ishihara, Akane
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Banyu Pharmaceutical Co., Ltd.
SOURCE: PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009015	A2	20040129	WO 2003-US22077	20030714
WO 2004009015	A3	20040304		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:	US 2002-396603P	P	20020718
	US 2002-417999P	P	20021011

OTHER SOURCE(S): MARPAT 140:122817
AB The invention discloses compns. comprising a NPY5 antagonist and an antiobesity agent, useful for the treatment and prevention of diabetes, obesity, and obesity-related disorders. The invention also discloses methods of treating or preventing obesity and obesity-related disorders in a subject in need thereof by administering a composition of the invention. The
invention further discloses pharmaceutical compns., medicaments, and kits useful in carrying out the methods.
IT **328232-23-1 328232-25-3 478014-44-7**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NPY5 antagonist-antiobesity agent combination for the prevention and treatment of diabetes, obesity, and obesity-related disorders)
RN 328232-23-1 CAPLUS
CN Spiro[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide, 3-oxo-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 328232-25-3 CAPLUS
CN Spiro[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide, 3-oxo-N-[5-(3-quinolinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 478014-44-7 CAPLUS
CN Spiro[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide, N-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-3-oxo- (9CI) (CA INDEX NAME)

L6 ANSWER 5 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:41269 CAPLUS
DOCUMENT NUMBER: 140:77038
TITLE: Preparation of 3-[heteroarylmethoxy]pyridines and their analogues as p38 map kinase inhibitors
INVENTOR(S): Murray, Christopher William; Hartshorn, Michael John; Frederickson, Martyn; Congreve, Miles Stuart; Padova, Alessandro; Woodhead, Steven John; Gill, Adrian Liam; Woodhead, Andrew James
PATENT ASSIGNEE(S): Astex Technology Limited, UK
SOURCE: PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004720	A1	20040115	WO 2003-GB2864	20030703
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			GB 2002-15383	A 20020703
			US 2002-393121P	P 20020703
			GB 2002-26149	A 20021108

OTHER SOURCE(S): MARPAT 140:77038
GI



I

AB Title compds. I [X-Y = CR2=CR3, CR2=N; R1 = H, halo, amino, etc.; R2-3 = H, alkyl, aryl, etc.; R4 = carboaryl, heteroaryl; R5 = halo, amino, carboxamido, etc.] are prepared For instance, 2-amino-3-benzyloxypyridine is prepared by alkylation of 2-amino-3-hydroxypyridine with benzyl chloride. A related example, 2-amino-3-[2-phenylbenzyloxy]pyridine has IC50 < 10μM for p38 map kinase. I are useful in the treatment of diseases ameliorated by inhibiting p38 MAP kinase.

IT **642084-52-4P**, 2-[2-Chloro-5-[[[[5-(tert-butyl)pyrazol-3-yl]amino]carbonyl]amino]benzyloxy]pyrazine **642085-03-8P**, N-(5-tert-Butyl-2H-pyrazol-3-yl)-N'-[4-chloro-3-(((pyridin-3-yl)oxy)methyl)phenyl]urea **642085-44-7P**, N-[4-Fluoro-3-(((pyrazin-2-yl)oxy)methyl)phenyl]-N'-(5-phenyl-1H-pyrazol-3-yl)urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-[heteroarylmethoxy]pyridines and their analogs as p38 map

L6 ANSWER 4 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

L6 ANSWER 5 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
kinase inhibitors for treatment of arthritis)

RN 642084-52-4 CAPLUS
CN Urea, N-[4-chloro-3-[(pyrazinyloxy)methyl]phenyl]-N'-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 642085-03-8 CAPLUS
CN Urea, N-[4-chloro-3-[(3-pyridinyloxy)methyl]phenyl]-N'-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 642085-44-7 CAPLUS
CN Urea, N-[4-fluoro-3-[(pyrazinyloxy)methyl]phenyl]-N'-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:913146 CAPLUS
DOCUMENT NUMBER: 139:395928
TITLE: Preparation of pyrazolylcarboxamides with donor-acceptor-donor structure for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur
INVENTOR(S): Schrader, Thomas; Riesner, Detlev; Rzepecki, Petra; Nagel-Steger, Luitgard; Wehner, Mark; Kirsten, Christian; Molt, Oliver; Zadmard, Reza; Aschermann, Katja
PATENT ASSIGNEE(S): Transmit Gesellschaft fuer Technologietransfer mbH, Germany
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003095429	A1	20031120	WO 2003-DE1500	20030509
W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, SC, SD, SG, TN, TT, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10221052	A1	20031204	DE 2002-10221052	20020510
PRIORITY APPLN. INFO.:			DE 2002-10221052 A	20020510

GI



I

AB Pyrazolylcarboxamides with a donor-acceptor-donor structure with donor-acceptor distances of 3.5-4.0 Å and acceptor-donor distances of 2.6-2.9 Å and which inhibit the formation of β-amyloid plaques and dissolve those already formed, were prepared for use in treating diseases in which abnormal protein folding occurs, such as Alzheimer's and prion diseases. These compds. identify peptides and proteins having a β-pleated sheet structure, form stable complexes therewith, and prevent the aggregation thereof into β-amyloid plaques. In addition, they decompose already existing β-amyloid plaques. Thus, 3-amino-1-tert-butoxycarbonyl-5-methyl-1H-pyrazole was treated with m-(ClCO)2C6H4 and deblocked to give the diamide I which inhibited β-amyloid plaque formation by Aβ(1-42) at 10mM.

L6 ANSWER 6 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
IT **625385-93-5P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolylcarboxamides with donor-acceptor-donor structure for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur)
RN 625385-93-5 CAPLUS
CN Urea, N,N'-bis(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:732768 CAPLUS
DOCUMENT NUMBER: 140:128610
TITLE: Aminopyrazole oligomers for β-sheet stabilization of peptides
AUTHOR(S): Rzepecki, P.; Wehner, M.; Molt, O.; Zadmard, R.; Harms, K.; Schrader, T.
CORPORATE SOURCE: Philipps-Universitaet Marburg, Department of Chemistry, Marburg, 35032, Germany
SOURCE: Synthesis (2003), (12), 1815-1826
CODEN: SYNTBF; ISSN: 0039-7881
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB A general concept for the stabilization of β-sheets by designed artificial ligands is introduced. The ligands have two key features: they contain acylated 3-aminopyrazoles with a DAD hydrogen bond donor and acceptor pattern, and they were synthesized as oligomers in order to multiply their hydrogen bond interactions with peptides in the β-sheet conformation. Dimeric aminopyrazoles, e.g. I, were accessible by reaction of the N1-Boc 3-amino-5-methylpyrazole with several acid dichlorides followed by a standard deprotection procedure with trifluoroacetic acid. For the oligomers, N1-PMB protection of new pyrazole amino acids followed by an iterative extension protocol with peptide coupling using PyClop or Mukaiyama's reagent led to the target compds. All protecting groups were subsequently removed in a final deprotection step with warm trifluoroacetic acid. Two dimeric key compds. I and II were examined by NMR at various temps., in NOESY expts. as well as by X-ray crystallog. in order to elucidate their conformational preference in solution and the solid state. The emerging picture was the same for all methods: both ligands adopt a flat conformation with a high degree of pre-orientation and the correct DAD pattern for optimal interaction with peptides in their extended conformation. Aggregation assays with the Prion protein and the Alzheimer's peptide Aβ (1-40) show highly promising results for some of the dimeric and oligomeric ligands at very low concns.
IT **625385-93-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of aminopyrazole dimers and oligomers for β-sheet stabilization of peptides and their aggregation assays)
RN 625385-93-5 CAPLUS
CN Urea, N,N'-bis(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 7 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:719393 CAPLUS
DOCUMENT NUMBER: 139:237797
TITLE: Heat sensitive recording material
INVENTOR(S): Henshall, John Barry; Taylor, James Philip
PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074285	A1	20030912	WO 2003-EP1900	20030225

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2002-405170 A 20020306
OTHER SOURCE(S): MARPAT 139:237797
AB The present invention relates to a composition for heat sensitive recording material containing (a) a color former compound, (b) a developer, which is different from the stabilizer used as component (c), (c) a stabilizer, selected from the group consisting of compds. having the formulas: R1SO2NHC(=X)NHR2, (R1SO2NHC(=X)NH)n-A, and R1S(=O)(=O)NHC(=X)NHY1 (R1 = Ph, naphthyl, C1-20 alkyl, C3-10 cycloalkyl, etc.), wherein the amount of the stabilizer is less than 5%, based on the total weight of the composition The present invention relates to a heat sensitive recording material comprising this composition and the use of this composition as heat-sensitive colored image-forming layer in heat-sensitive materials.
IT **144849-11-6**
RL: TEM (Technical or engineered material use); USES (Uses)
(heat sensitive recording material containing)
RN 144849-11-6 CAPLUS
CN Benzenesulfonamide, 4-methyl-N-[[(5-methyl-1H-pyrazol-3-yl)amino]carbonyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 8 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:656752 CAPLUS
DOCUMENT NUMBER: 139:197392
TITLE: Preparation of N-carbamoyl nitrogen-containing fused ring compounds as mitochondrial benzodiazepine receptor (MBR) antagonists
INVENTOR(S): Seko, Takuya; Katsumata, Seishi; Kato, Masashi; Manako, Jun-ichiro; Ohmoto, Kazuyuki
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 222 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068753	A1	20030821	WO 2003-JP1481	20030213

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2002-36340 A 20020214
OTHER SOURCE(S): MARPAT 139:197392
GI



I

AB The title compds. (I) [wherein the ring A = C5-8 monocyclic carbocyclic ring or 5- to 8-membered monocyclic heterocyclic ring containing 1 or 2 N, 1 or 2 O and/or one S atom; X = CH2, O, S, SO, SO2; L1, L2 = a single bond, C1-4 alkylene, C2-4 alkenylene, provided that a sum total of C atoms in L1 and L2 is 3 or 4; R1 , R2 = each (un)substituted C1-8 alkyl, C2-8 alkenyl, or C2-8 alkynyl, ring B, OR5, NR6R7, COR8, O2CR8, O2CNR6R7, CO2R8, CONR6R7, SR9, SOR8, SO2R8, SO2NR6R7, halo, CO2H, cyano, NO2, oxo, etc.; the ring B = (un)substituted C3-10 monocyclic or dicyclic carbocyclic ring or monocyclic or dicyclic heterocyclic ring containing 1 or 2 N, 1 or 2 O and/or one S atom; R5 = each (un)substituted C1-8 alkyl, C2-8 alkenyl, or C2-8 alkynyl, etc.; R6, R7 = H, -D1-D2 (wherein D1 = a single bond, CO, CO2, or SO2; D2 = each (un)substituted C1-8 alkyl, C2-8 alkenyl, or C2-8 alkynyl, etc.); R8 = groups listed in D2; R9 = each (un)substituted C1-8 alkyl, C2-8 alkenyl, or C2-8 alkynyl, ring B; R3 = H, ring B, each (un)substituted C1-8 alkyl, C2-8 alkenyl, or C2-8 alkynyl; R4 = H, C1-8 alkyl, C2-8 alkenyl, or C2-8 alkynyl; or NR3R4 = (un)substituted 5- to 10-membered monocyclic or dicyclic heterocyclyl containing one N atom and optionally 1-3 N, one O, and/or one S atoms; m, n = an integer of 0-4; W = O, S] were prepd. Also disclosed are mitochondrial benzodiazepine receptor (MBR) antagonists comprising these compds. I and preventives and/or remedies for diseases caused by stress which comprise the above compds. I as the active ingredient. Because of having an MBR antagonistic activity and inhibiting the prodn. of neurosteroids, the compds. I are useful as preventives and/or remedies for diseases caused by stress. The diseases induced, worsened, or exacerbated by stress include digestive organ disease, circulatory system disease, endocrine-metabolic disease, respiratory disease, nerve-muscular disease, skin disease, surgical disease, orthopedic disease, urinary organ-reproductive disease, gynecol. disease (gynopathy), eye disease, otolaryngol. (ear, nose and throat) disease, dental-oral surgical disease, and cancer. The digestive organ disease include functional indigestion, stomach-duodenal ulcer,ulcerative colitis, irritable bowel syndrome, biliary tract dyskinesia, esophagism, gastroatonia (atony of stomach), chronic hepatitis, and chronic pancreatitis. Thus, 250 mg Ph isocyanate was added to a soln. of 560 mg 5-(tert-butyldimethylsilyloxy)-2,3,4,5-tetrahydro-1H-1-benzazepine (prepn. given) in toluene and refluxed overnight to give, after silica gel chromatog., 655 mg 5-(tert-butyldimethylsilyloxy)-1-phenylcarbamoyl-2,3,4,5-tetrahydro-1H-1-benzazepine. The latter compd. (676 mg) was dissolved in 3 mL THF, treated with 2 mL 1 M Bu4NF, and stirred for 5 h to give, after silica gel chromatog., 459 mg 5-hydroxy-1-phenylcarbamoyl-2,3,4,5-tetrahydro-1H-1-benzazepine. 1-(2,6-Dichlorophenylcarbamoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine in vitro inhibited the binding of [3H]PK11195 (MBR-selective ligand) to rat brain membrane sample with Ki of 0.09 nM. A tablet formulation contg. 8-fluoro-5-(4-fluorophenyl)-1-(4-hydroxyphenylcarbamoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine was described.
IT **585577-29-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carbamoyl nitrogen-containing fused ring compds. as mitochondrial benzodiazepine receptor antagonists for treating or preventing diseases caused by stress)
RN 585577-29-3 CAPLUS
CN 1H-1-Benzazepine-1-carboxamide, 2,3,4,5-tetrahydro-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

L6 ANSWER 10 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:356201 CAPLUS
DOCUMENT NUMBER: 138:368888
TITLE: Pyrazolecarboxamides and -sulfonamides as sodium channel blockers
INVENTOR(S): Atkinson, Robert Nelson; Gross, Michael Francis
PATENT ASSIGNEE(S): Icagen, Inc., USA
SOURCE: PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003037274	A2	20030508	WO 2002-US35172	20021101
WO 2003037274	A3	20031030		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-335958P P 20011101
OTHER SOURCE(S): MARPAT 138:368888
GI



I

AB Pyrazolecarboxamides and -sulfonamides were prepared for use in the treatment of diseases through the inhibition of sodium ion flux through voltage-dependent sodium channels, especially pain and chronic pain. Thus, the amide I was prepared by amidation of the acid chloride with the amine and showed activity at the PN3 Na channel in the 4.1-10 μM range.

IT **521930-91-6P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolecarboxamides and -sulfonamides as sodium channel blockers)

RN 521930-91-6 CAPLUS
CN Urea, N-[1-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]-N'-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L6 ANSWER 11 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:947029 CAPLUS
DOCUMENT NUMBER: 138:24705
TITLE: Preparation of spiroisoindolinepiperidinecarboxamides, spirocyclohexaneisobenzofurancarboxamides, spiroazaisobenzofurancyclohexanecarboxamides, and related compounds as neuropeptide Y antagonists.
INVENTOR(S): Fukami, Takehiro; Kanatani, Akio; Ishihara, Akane; Ishii, Yasuyuki; Takahashi, Toshiyuki; Haga, Yuji; Sakamoto, Toshihiro; Itoh, Takahiro
PATENT ASSIGNEE(S): Japan
SOURCE: U.S. Pat. Appl. Publ., 53 pp., Cont.-in-part of U.S. Pat. Appl. 2002 52,371.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002188124	A1	20021212	US 2002-92549	20020308
US 6326375	B1	20011204	US 2000-640784	20000818
US 6335345	B1	20020101	US 2001-928431	20010814
US 2002052371	A1	20020502	US 2001-983598	20011025
US 6388077	B2	20020514		
ZA 2002000734	A	20030128	ZA 2002-734	20020128
US 6462053	B2	20021008	US 2002-101221	20020320
US 2002165391	A1	20021107		
US 2003055251	A1	20030320	US 2002-226225	20020823
US 6649624	B2	20031118		
JP 2003104884	A2	20030409	JP 2002-271261	20020918
JP 3553560	B2	20040811		
WO 2003076443	A1	20030918	WO 2003-JP2611	20030305

W: AE, AG, AL, AM, AU, AZ, BA, BB, BR, BY, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GH, HR, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, RU, SC, SG, TJ, TM, TN, TT, UA, US, UZ, VC, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003220499	A1	20031127	US 2003-453737	20030604
US 6723847	B2	20040420		

PRIORITY APPLN. INFO.:
JP 1999-233573 A 19990820
JP 2000-137692 A 20000510
US 2000-640784 A3 20000818
US 2001-983598 A2 20011025
JP 2000-247145 A3 20000817
US 2002-92549 A 20020308
US 2002-101221 A3 20020320
US 2002-226225 A3 20020823

OTHER SOURCE(S): MARPAT 138:24705
GI

L6 ANSWER 11 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB Title compds. [I; Ar1 = (substituted) aryl, heteroaryl, QAr2; Ar2 = (substituted) aryl, heteroaryl; Q = bond, CO; T, U, V, W = N, (substituted) CH; X = CH, CH(OH); Y = (substituted) imino, O], were prepared Thus, N-tert-butoxycarbonyl-4-piperidone was refluxed 3 h with PhCH2NH2 in PhMe to give a residue which was stirred with o-iodobenzoyl chloride and Et3N in PhMe at 80° for 2 h to give N-benzyl-N-(1-tert-butoxycarbonyl-1,2,3,6-tetrahydropyridin-4-yl)-2-iodobenzamide. The latter was heated with Pd(OAc)2, Ph3P, K2CO3, and Et4NCl in MeCN at 80° for 6 h to give 2-benzyl-1'-tert-butoxycarbonyl-1',6'-dihydrospiro[1H-isoindole-1,4'(5'H)-pyridine]-3(2H)-one. This was converted to N-(4-benzoylphenyl)-3-oxospiro[isoindoline-1,4'-piperidine]-1'-carboxamide (II), which inhibited [125I]neuropeptide Y binding to NPY Y5 receptors with IC50 = 1.2 nM. II drug formulations are given.

IT **328232-23-1P 328232-25-3P 478014-44-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of spiroisoindolinepiperidinecarboxamides, spirocyclohexaneisobenzofurancarboxamides, spiroazaisobenzofurancyclohexanecarboxamides, and related compds. as neuropeptide Y antagonists)

RN 328232-23-1 CAPLUS
CN Spiro[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide, 3-oxo-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 11 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 328232-25-3 CAPLUS
CN Spiro[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide, 3-oxo-N-[5-(3-quinolinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 478014-44-7 CAPLUS
CN Spiro[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide, N-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-3-oxo- (9CI) (CA INDEX NAME)

L6 ANSWER 11 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

L6 ANSWER 12 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:695980 CAPLUS
DOCUMENT NUMBER: 137:232544
TITLE: Tricycloalkatrienes as non-nucleoside reverse transcriptase inhibitors
INVENTOR(S): Lindstroem, Stefan; Sahlberg, Christer; Wallberg, Hans; Kalyanov, Genaidy; Oden, Lourdes; Naeslund, Lotta
PATENT ASSIGNEE(S): Medivir AB, Swed.
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002070516	A2	20020912	WO 2002-EP2328	20020304
WO 2002070516	A3	20030206		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1373261	A2	20040102	EP 2002-748329	20020304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003069224	A1	20030410	US 2002-92752	20020305
US 6716850	B2	20040406		
US 2003187266	A1	20031002	US 2003-377057	20030228
PRIORITY APPLN. INFO.:			SE 2001-733	A 20010305
			WO 2002-EP2328	W 20020304
			US 2002-92752	A3 20020305

OTHER SOURCE(S): MARPAT 137:232544
GI

L6 ANSWER 12 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I



II

AB Title compds. I [R1 = O, S; R2 = (un)substituted nitrogen-containing heterocycle, wherein the nitrogen is located at the 2 position relative to the (thio)urea bond; R3 = H, alkyl; R4-R7 = H, alkyl, alkenyl, alkynyl, haloalkyl, alkanoyl, haloalkanoyl, alkoxy, haloalkoxy, alkyloxyalkyl, haloalkyloxylkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, cyanoalkyl, amino, carboxy, carbamoyl, cyano, halo, hydroxy, keto; X = (CHR8)nD(CHR8)m; D = NR9, O, S, S(=O), SO2; R8 = H, alkyl, haloalkyl; R9 = H, alkyl; n, m = 0, 1, 2] and prodrugs and pharmaceutically acceptable salts thereof, have utility as inhibitors of HIV-1 reverse transcriptase, particularly drug escape mutants. Thus, benzothiophene was treated with N2CHCO2Et to give Et cis-1a,6b-dihydro-1H-benzo[b]cyclopropa[d]thiophene-1-carboxylate which was hydrolyzed to the acid and treated with (PhO)2PN3 and 2-amino-6-cyanopyridine to give the urea II. II had ED50 in the XTT assay with wild-type HIV-1IIIB of 2 nM.

IT **457627-96-2P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tricycloalkatrienes as non-nucleoside reverse transcriptase inhibitors)

RN 457627-96-2 CAPLUS

CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[(1S,1aR,7bR)-4,7-difluoro-1,1a,2,7b-tetrahydrobenzo[b]cyclopropa[d]pyran-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 12 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L6 ANSWER 13 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:658091 CAPLUS
DOCUMENT NUMBER: 137:185488
TITLE: Preparation of N-aryl-N'-azolylureas
INVENTOR(S): Tan, Zhulin; Song, Jinhua J.
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066442	A1	20020829	WO 2002-US2982	20020101
W: CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1362037	A1	20031119	EP 2002-707665	20020101
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2004518739	T2	20040624	JP 2002-565959	20020101
US 2002123631	A1	20020905	US 2002-74895	20020212
PRIORITY APPLN. INFO.:			US 2001-268841P P	20010215
			WO 2002-US2982 W	20020101
OTHER SOURCE(S):	CASREACT 137:185488; MARPAT 137:185488			

GI



I

AB Title compds. were prepared Thus, 4-[2-(4-morpholinyl)ethoxy]-1-naphthaleneamine was N-acylated by ClCO2CH2CCl3 and the product amidated by 5-(1,1,-dimethylethyl)-1H-pyrazole-3-amine to give, after N-arylation, title compound I.

IT **451480-58-3P**
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-aryl-N'-azolylureas)

RN 451480-58-3 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-[4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:591913 CAPLUS
DOCUMENT NUMBER: 137:150215
TITLE: Cdk4 and/or Cdk6 inhibitors with biaryl ureas and their salts as antitumor agents
INVENTOR(S): Hatayama, Satoshi; Hayashi, Kyoko; Honma, Mitsuki; Takahashi, Ikuko
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 194 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002220338	A2	20020809	JP 2001-18755	20010126
PRIORITY APPLN. INFO.:			JP 2001-18755	20010126
OTHER SOURCE(S):	MARPAT 137:150215			

GI



I

AB This invention relates to the general structures (I; Ar = N-containing hetero
aromatic ring, X, Z = C, etc.; Y = CO, etc.; R1-R5 = H, etc.) and their salts
as Cdk4 and/or Cdk6 inhibitors. I have antiproliferative effects on cancer cells and are potential antitumor agents. Formulation examples of I capsules, tablets, and injections were given.

IT **322681-94-7 322683-91-0 322688-41-5**
322688-44-8 322688-45-9 322688-46-0
322688-47-1 322688-49-3 322688-51-7
322688-53-9 322688-55-1 322688-57-3
322688-58-4 322688-60-8 322688-62-0
322688-64-2 322688-65-3 322688-67-5
322688-69-7 322688-70-0 322688-73-3
322688-74-4 322688-75-5 322688-78-8
322688-79-9 322688-80-2 322688-81-3
322688-82-4 322688-84-6 322688-85-7
322688-87-9 322688-92-6 322688-93-7
322688-95-9 322688-97-1 322688-98-2
322689-00-9 322689-08-7 322689-09-8
322689-18-9 322689-19-0 322689-20-3
322689-21-4 322689-22-5 322689-27-0
322689-29-2 322689-30-5 322689-40-7

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
322689-49-6 322689-50-9 322689-51-0
322689-52-1 322689-53-2 322689-54-3
322689-55-4 322689-56-5 322689-57-6
322689-58-7 322689-59-8 322689-60-1
322689-71-4 322689-72-5 322689-73-6
322689-74-7 322689-75-8 322689-76-9
322689-77-0 322689-78-1 322689-79-2
322689-80-5 322689-81-6 322689-82-7
322689-83-8 322689-84-9 322689-85-0
322689-86-1 322689-89-4 322689-90-7
322689-91-8 322689-92-9 322689-93-0
322689-94-1 322689-95-2 322689-96-3
322689-97-4 322689-98-5 322689-99-6
322690-00-6 322690-01-7 322690-02-8
322690-03-9 322692-20-6 322692-24-0
322692-31-9 445431-71-0 445431-72-1
445431-76-5 445431-80-1 445431-82-3
445431-83-4 445431-84-5 445431-85-6
445431-86-7 445431-87-8 445431-89-0
445431-90-3 445431-91-4 445431-92-5
445432-09-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Cdk4 and/or Cdk6 inhibitors with biaryl ureas and their salts as antitumor agents)

RN 322681-94-7 CAPLUS
CN Urea, N-(9-oxo-9H-fluoren-4-yl)-N'-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 322683-91-0 CAPLUS
CN Urea, N-(5-phenyl-1H-pyrazol-3-yl)-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-41-5 CAPLUS
CN Urea, N-[5-(hydroxymethyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-44-8 CAPLUS
CN Urea, N-[5-[[(1-ethylpropyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-45-9 CAPLUS
CN Urea, N-[5-[[(2-methylpropyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-46-0 CAPLUS
CN Urea, N-[5-[[(2,2-dimethylpropyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-47-1 CAPLUS
CN Urea, N-[5-[[(1,1-dimethylpropyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-49-3 CAPLUS
CN Urea, N-[5-[[(2-methylphenyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 322688-51-7 CAPLUS
CN Urea, N-[5-[[(3-methylphenyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 322688-53-9 CAPLUS
CN Urea, N-[5-[[(4-methylphenyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 322688-55-1 CAPLUS
CN Urea, N-[5-[[[2-(1-methylethyl)phenyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 322688-57-3 CAPLUS
CN Urea, N-[5-[[[3-(1-methylethyl)phenyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 322688-58-4 CAPLUS
CN Urea, N-[5-[[[4-(1-methylethyl)phenyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 322688-60-8 CAPLUS
CN Urea, N-[5-[[(2,3-dihydro-1H-inden-1-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 322688-62-0 CAPLUS
CN Urea, N-[5-[[(1-phenylethyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-64-2 CAPLUS
CN Urea, N-[5-[[(1-methylheptyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-65-3 CAPLUS
CN Urea, N-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)-N'-[5-[[(1,1,3,3-tetramethylbutyl)amino]methyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-70-0 CAPLUS
CN Urea, N-[5-[[(2-hydroxy-1,1-dimethylethyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-73-3 CAPLUS
CN Urea, N-[5-[[(hexahydro-2-oxo-1H-azepin-3-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-67-5 CAPLUS
CN Urea, N-[5-[[(2,3-dihydro-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-69-7 CAPLUS
CN Urea, N-[5-[[[1-(hydroxymethyl)propyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 322688-74-4 CAPLUS
CN Urea, N-[5-[(cyclododecylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 322688-75-5 CAPLUS
CN Urea, N-[5-[[[1-(hydroxymethyl)cyclopentyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 322688-78-8 CAPLUS
CN Urea, N-[5-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 322688-79-9 CAPLUS
CN Urea, N-[5-[(1-azabicyclo[2.2.2]oct-3-ylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-80-2 CAPLUS
CN Urea, N-[5-[[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322688-81-3 CAPLUS
CN Urea, N-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)-N'-[5-[[[1-(3-thienylmethyl)-4-piperidinyl]amino]methyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 322688-82-4 CAPLUS
CN Urea, N-[5-[[(2,3-dihydro-5,6-dimethoxy-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-84-6 CAPLUS
CN Urea, N-[5-[[(5-chloro-2,3-dihydro-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-85-7 CAPLUS
CN Urea, N-[5-[[(2,3-dihydro-4-methoxy-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-87-9 CAPLUS
CN Urea, N-[5-[[(2,3-dihydro-5-methoxy-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-92-6 CAPLUS
CN Urea, N-[5-[[(5-fluoro-2,3-dihydro-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-93-7 CAPLUS
CN Urea, N-[5-[[(5-bromo-2,3-dihydro-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-95-9 CAPLUS
CN Urea, N-[5-[[(4-chloro-2,3-dihydro-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-97-1 CAPLUS
CN Urea, N-[5-[[(2,3-dihydro-2-methyl-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-98-2 CAPLUS
CN Urea, N-[5-[[(2,3-dihydro-1H-benz[f]inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-09-8 CAPLUS
CN Urea, N-[5-[[(5-chloro-2,3-dihydro-1H-inden-2-yl)methylamino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-18-9 CAPLUS
CN Urea, N-[5-(2-methylphenyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-00-9 CAPLUS
CN Urea, N-[5-[[(2,3-dihydro-1H-benz[e]inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-08-7 CAPLUS
CN Urea, N-[5-[[(1,1-dimethylethyl)methylamino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-19-0 CAPLUS
CN Urea, N-[5-(2-naphthalenyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-20-3 CAPLUS
CN Urea, N-[5-(6-methyl-2-pyridinyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-21-4 CAPLUS
CN Urea, N-[5-(1-naphthalenyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-22-5 CAPLUS
CN Urea, N-[5-(3-methylphenyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-30-5 CAPLUS
CN Urea, N-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)-N'-[5-(2-thienyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 322689-40-7 CAPLUS
CN Urea, N-[5-[(2S)-5-oxo-1-(phenylmethyl)-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-27-0 CAPLUS
CN Urea, N-[5-(2-pyridinyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-29-2 CAPLUS
CN Urea, N-[5-[5-methyl-1-(phenylmethyl)-1H-imidazol-4-yl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-49-6 CAPLUS
CN Urea, N-[5-[1-(cyclohexylamino)ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

RN 322689-50-9 CAPLUS
CN Urea, N-(5-acetyl-1H-pyrazol-3-yl)-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-51-0 CAPLUS
CN Urea, N-[5-[1-(phenylmethoxy)ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-52-1 CAPLUS
CN Urea, N-[5-[1-[(phenylmethyl)amino]ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-53-2 CAPLUS
CN Urea, N-[5-(1-hydroxyethyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-54-3 CAPLUS
CN Urea, N-[5-[1-(ethylamino)ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-55-4 CAPLUS
CN Urea, N-[5-[1-(propylamino)ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-56-5 CAPLUS
CN Urea, N-[5-[1-[[(1R)-1-phenylethyl]amino]ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322689-57-6 CAPLUS
CN Urea, N-[5-[1-(cyclopentylamino)ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 322689-58-7 CAPLUS
CN Urea, N-[5-[1-(cyclopropylamino)ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 322689-59-8 CAPLUS
CN Urea, N-[5-[1-[(1-methylethyl)amino]ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-60-1 CAPLUS
CN Urea, N-[5-[1-(1-piperidinyl)ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

RN 322689-71-4 CAPLUS
CN Urea, N-[5-[(butylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-72-5 CAPLUS
CN Urea, N-[5-[(cyclohexylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 322689-73-6 CAPLUS
CN Urea, N-[5-[[(phenylmethyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-74-7 CAPLUS
CN Urea, N-[5-[(propylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-75-8 CAPLUS
CN Urea, N-[5-[[(1-methylethyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-76-9 CAPLUS
CN Urea, N-[5-[[(1,1-dimethylethyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-77-0 CAPLUS
CN Urea, N-[5-[(dimethylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-78-1 CAPLUS
CN Urea, N-[5-(1-piperidinylmethyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

RN 322689-79-2 CAPLUS
CN Urea, N-[5-(1-pyrrolidinylmethyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-80-5 CAPLUS
CN Urea, N-[5-[(methylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-81-6 CAPLUS
CN Urea, N-[5-[(cycloheptylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

RN 322689-82-7 CAPLUS
CN Urea, N-[5-[(cyclopentylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 322689-83-8 CAPLUS
CN Urea, N-[5-[[(1-methylpropyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-84-9 CAPLUS
CN Urea, N-[5-[[(1-methylbutyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-85-0 CAPLUS
CN Urea, N-[5-[[(1-methylpentyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-86-1 CAPLUS
CN Urea, N-[5-[[(1-methylhexyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-89-4 CAPLUS
CN Urea, N-[5-[[(1,2-dimethylpropyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-92-9 CAPLUS
CN Urea, N-[5-[[[(1R)-1-(4-methylphenyl)ethyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322689-93-0 CAPLUS
CN Urea, N-[5-[[[(1S)-1-(4-methylphenyl)ethyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-90-7 CAPLUS
CN Urea, N-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)-N'-[5-[[(1,2,2-trimethylpropyl)amino]methyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 322689-91-8 CAPLUS
CN Urea, N-[5-[[(1-methyl-1-phenylethyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-94-1 CAPLUS
CN Urea, N-[5-[[[(1R)-1-(1-naphthalenyl)ethyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322689-95-2 CAPLUS
CN Urea, N-[5-[[[(1S)-1-(1-naphthalenyl)ethyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-96-3 CAPLUS
CN Urea, N-[5-[[[(1R)-1-cyclohexylethyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322689-97-4 CAPLUS
CN Urea, N-[5-[[[4-(diethylamino)-1-methylbutyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

RN 322689-99-6 CAPLUS
CN Urea, N-[5-[[[2-(1H-indol-3-yl)-1-methylethyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 322690-00-6 CAPLUS
CN Urea, N-[5-[[[(1R)-1-methyl-3-phenylpropyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-98-5 CAPLUS
CN Urea, N-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)-N'-[5-[[(1-tricyclo[3.3.1.13,7]dec-1-ylethyl)amino]methyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.



RN 322690-01-7 CAPLUS
CN Urea, N-[5-[[(2-methoxy-1-methylethyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322690-02-8 CAPLUS
CN Urea, N-[5-[[(5-bromo-2,3-dihydro-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-2,3-dimethyl-5-oxooxazolo[2,3-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322690-03-9 CAPLUS
CN Urea, N-[5-[[(5-bromo-2,3-dihydro-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(3,4,6,10b-tetrahydro-2,3-dimethyl-6-oxo-2H-[1,3]oxazino[2,3-a]isoindol-10-yl)- (9CI) (CA INDEX NAME)



RN 322692-20-6 CAPLUS
CN Urea, N-[5-[(4-methyl-1-piperazinyl)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 322692-24-0 CAPLUS
CN Urea, N-[5-[(2S)-1-(phenylmethyl)-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322692-31-9 CAPLUS
CN Urea, N-[5-[(2S)-1-methyl-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445431-71-0 CAPLUS
CN Urea, N-[5-[[[1-(hydroxymethyl)-2-phenylethyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 445431-72-1 CAPLUS
CN Urea, N-[5-[[[(1S)-1-(hydroxymethyl)-2,2-dimethylpropyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445431-76-5 CAPLUS
CN Urea, N-[5-[[(4,5-dichloro-2,3-dihydro-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 445431-80-1 CAPLUS
CN Urea, N-[5-[(2R)-1-(phenylmethyl)-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445431-82-3 CAPLUS
CN Urea, N-[5-(2R)-2-pyrrolidinyl-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 445431-83-4 CAPLUS
CN Urea, N-[5-(2S)-2-pyrrolidinyl-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445431-84-5 CAPLUS
CN Urea, N-(5-cyclopentyl-1H-pyrazol-3-yl)-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 445431-85-6 CAPLUS
CN Urea, N-[5-[(2S,4R)-4-(phenylmethoxy)-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445431-86-7 CAPLUS
CN Urea, N-[5-[(2S,4R)-4-hydroxy-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 445431-87-8 CAPLUS
CN Urea, N-[5-[5-oxo-1-(phenylmethyl)-3-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 445431-89-0 CAPLUS
CN Urea, N-[5-[(2S)-1-formyl-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 445431-90-3 CAPLUS
CN Urea, N-[5-[1-(butylamino)ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 445431-91-4 CAPLUS
CN Urea, N-[5-[[(1,5-dimethylhexyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L6 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 445431-92-5 CAPLUS
CN Urea, N-[5-[[(3-methylbutyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 445432-09-7 CAPLUS
CN Urea, N-[5-[[(5-bromo-2,3-dihydro-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(3,4,6,10b-tetrahydro-3-methyl-6-oxo-2H-[1,3]oxazino[2,3-a]isoindol-10-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 15 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:892349 CAPLUS
DOCUMENT NUMBER: 136:146987
TITLE: A Novel Approach for the Development of Selective Cdk4 Inhibitors: Library Design Based on Locations of Cdk4 Specific Amino Acid Residues
AUTHOR(S): Honma, Teruki; Yoshizumi, Takashi; Hashimoto, Noriaki; Hayashi, Kyoko; Kawanishi, Nobuhiko; Fukasawa, Kazuhiro; Takaki, Tohru; Ikeura, Chinatsu; Ikuta, Mari; Suzuki-Takahashi, Ikuko; Hayama, Takashi; Nishimura, Susumu; Morishima, Hajime
CORPORATE SOURCE: Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories, Tsukuba, Ibaraki, 300-2611, Japan
SOURCE: Journal of Medicinal Chemistry (2001), 44(26), 4628-4640
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Identification of a selective inhibitor for a particular protein kinase without inhibition of other kinases is critical for use as a biol. tool or drug. However, this is very difficult because there are hundreds of homologous kinases and their kinase domains including the ATP binding pocket have a common folding pattern. To address this issue, the authors applied the following structure-based approach for designing selective Cdk4 inhibitors: (1) identification of specifically altered amino acid residues around the ATP binding pocket in Cdk4 by comparison of 390 representative kinases, (2) prediction of appropriate positions to introduce substituents in lead compds. based on the locations of the altered amino acid residues and the binding modes of lead compds., and (3) library design to interact with the altered amino acid residues supported by de novo design programs. Accordingly, Asp99, Thr102, and Gln98 of Cdk4, which are located in the p16 binding region, were selected as first target residues for specific interactions with Cdk4. Subsequently, the 5-position of the pyrazole ring in the pyrazol-3-ylurea class of lead compound was predicted to be a suitable position to introduce substituents. The authors then designed a chemical library of pyrazol-3-ylurea substituted with alkylaminomethyl groups based on the output structures of de novo

L6 ANSWER 15 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
design programs. Thus the authors identified a highly selective and potent Cdk4 inhibitor (I), substituted with a 5-chloroindan-2-ylaminomethyl group. Compd. I showed higher selectivity on Cdk4 over those on not only Cdk1/2 (780-fold/190-fold) but also many other kinases (>430-fold) that have been tested thus far. The structural basis for Cdk4 selective inhibition by I was analyzed by combining mol. modeling and the x-ray anal. of the Cdk4 mimic Cdk2-inhibitor complex. The results suggest that the hydrogen bond with the carboxyl group of Asp99 and hydrophobic van der Waals contact with the side chains of Thr102 and Gln98 are important. Compd. I was found to cause cell cycle arrest of the Rb(+) cancer cell line in the G1 phase, indicating that it is a good biol. tool.

IT **322689-01-0P**
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel approach for development of selective Cdk4 inhibitors and library design of pyrazolylureas based on locations of Cdk4 specific amino acid residues in relation to antitumor activity)

RN 322689-01-0 CAPLUS
CN Urea, N-[5-[[[(2S)-5-chloro-2,3-dihydro-1H-inden-2-yl]amino]methyl]-1H-pyrazol-3-yl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **322689-07-6P 322689-72-5P 322689-74-7P**
322689-75-8P 322689-76-9P 322689-78-1P
322689-79-2P 322689-80-5P 322689-82-7P
393590-69-7P 393590-70-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(novel approach for development of selective Cdk4 inhibitors and library design of pyrazolylureas based on locations of Cdk4 specific amino acid residues in relation to antitumor activity)

RN 322689-07-6 CAPLUS
CN Urea, N-[5-[[[(2S)-5-chloro-2,3-dihydro-1H-inden-2-yl]amino]methyl]-1H-

L6 ANSWER 15 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

RN 322689-74-7 CAPLUS
CN Urea, N-[5-[(propylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-75-8 CAPLUS
CN Urea, N-[5-[[(1-methylethyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



L6 ANSWER 15 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
pyrazol-3-yl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322689-72-5 CAPLUS
CN Urea, N-[5-[(cyclohexylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 15 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 322689-76-9 CAPLUS
CN Urea, N-[5-[[(1,1-dimethylethyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-78-1 CAPLUS
CN Urea, N-[5-(1-piperidinylmethyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 15 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

RN 322689-79-2 CAPLUS
CN Urea, N-[5-(1-pyrrolidinylmethyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-80-5 CAPLUS
CN Urea, N-[5-[(methylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 15 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-82-7 CAPLUS
CN Urea, N-[5-[(cyclopentylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 15 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

RN 393590-69-7 CAPLUS
CN Urea, N-[5-[[(2S)-1-(phenylmethyl)-2-pyrrolidinyl]methyl]-1H-pyrazol-3-yl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393590-70-0 CAPLUS
CN Urea, N-[5-[[(2S)-1-(phenylmethyl)-2-pyrrolidinyl]methyl]-1H-pyrazol-3-yl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 15 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **322688-41-5P 322693-26-5P 393590-64-2P**
393590-68-6P 393590-75-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(novel approach for development of selective Cdk4 inhibitors and library design of pyrazolylureas based on locations of Cdk4 specific amino acid residues in relation to antitumor activity)

RN 322688-41-5 CAPLUS
CN Urea, N-[5-(hydroxymethyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322693-26-5 CAPLUS
CN Urea, N-(5-formyl-1H-pyrazol-3-yl)-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 15 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 393590-64-2 CAPLUS
CN Urea, N-[5-[(phenylmethoxy)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 393590-68-6 CAPLUS
CN Urea, N-[5-[[(2S)-1-(phenylmethyl)-2-pyrrolidinyl]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 15 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 393590-75-5 CAPLUS
CN Urea, N-[5-[[[(2S)-5-chloro-2,3-dihydro-1H-inden-2-yl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:746592 CAPLUS
DOCUMENT NUMBER: 136:95577
TITLE: Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach
AUTHOR(S): Smith, R. A.; Barbosa, J.; Blum, C. L.; Bobko, M. A.; Caringal, Y. V.; Dally, R.; Johnson, J. S.; Katz, M. E.; Kennure, N.; Kingery-Wood, J.; Lee, W.; Lowinger, T. B.; Lyons, J.; Marsh, V.; Rogers, D. H.; Swartz, S.; Walling, T.; Wild, H.
CORPORATE SOURCE: Department of Chemistry Research, Bayer Research Center, West Haven, CT, 06516, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(20), 2775-2778
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Heterocyclic ureas, such as N-3-thienyl N'-aryl ureas, have been identified as novel inhibitors of raf kinase, a key mediator in the ras signal transduction pathway. Structure-activity relationships were established, and the potency of the screening hit was improved 10-fold to IC50=1.7 μM. A combinatorial synthesis approach enabled the identification of a breakthrough lead (IC50=0.54 μM) for a second generation series of heterocyclic urea raf kinase inhibitors.
IT 389069-99-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heterocyclic ureas as raf kinase inhibitors)
RN 389069-99-2 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(1,1-dimethylethyl)-3-[[[(5-methyl-1H-pyrazol-3-yl)amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 17 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:581885 CAPLUS
DOCUMENT NUMBER: 135:152803
TITLE: Preparation of 3-aminopyrazole inhibitors of cyclin dependent kinases
INVENTOR(S): Salvati, Mark E.; Kimball, Spencer David
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001057034	A1	20010809	WO 2001-US2208	20010123
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1268472	A1	20030102	EP 2001-948983	20010123
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003522174	T2	20030722	JP 2001-557866	20010123
US 2001047019	A1	20011129	US 2001-777273	20010206
US 6482842	B2	20021119		
US 2003018058	A1	20030123	US 2002-219844	20020815
US 6610724	B2	20030826		
PRIORITY APPLN. INFO.:			US 2000-180609P	P 20000207
			WO 2001-US2208	W 20010123
			US 2001-777273	A3 20010206

OTHER SOURCE(S): MARPAT 135:152803
GI



AB The title compds. [I; R1 = R2, COR3, CONH2, etc.; R2 = H, alkyl, cycloalkyl, etc.; R3 = alkyl, cycloalkyl, aryl, etc.; A = (CR7R8)jY(CR5R6)iR4 (wherein i, j = 0-1 but cannot both be 1; Y = ethylene, alkene, alkyne or any 2 adjacent carbon atoms of a cycloalkyl or heterocycloalkyl ring of 3-7 atoms; R4 = alkyl, cycloalkyl, aryl; R5-R8 =

L6 ANSWER 17 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
H, alkyl, cycloalkyl, etc.)] which are protein kinase inhibitors (no data given) and are useful in the treatment of proliferative diseases, for example, cancer, inflammation and arthritis, were prepd. E.g., a multi-step synthesis of the pyrazole II was given. Compds. I may also be useful in the treatment of Alzheimer's disease, and cardiovascular disease.

IT **352533-14-3P 352533-20-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-aminopyrazole inhibitors of cyclin dependent kinases)

RN 352533-14-3 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N'-[5-[(1Z)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 352533-20-1 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N'-[5-[(1E)-2-[5-(1,1-dimethylethyl)-2-oxazolyl]ethenyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:549128 CAPLUS
DOCUMENT NUMBER: 135:238519
TITLE: Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein
AUTHOR(S): Ikuta, Mari; Kamata, Kenji; Fukasawa, Kazuhiro; Honma, Teruki; Machida, Takumitsu; Hirai, Hiroshi; Suzuki-Takahashi, Ikuko; Hayama, Takashi; Nishimura, Susumu
CORPORATE SOURCE: Banyu Tsukuba Research Institute / Merck Research Laboratories, Tsukuba, 300-2611, Japan
SOURCE: Journal of Biological Chemistry (2001), 276(29), 27548-27554
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Genetic alteration of one or more components of the p16INK4A-CDK4,6/cyclin D-retinoblastoma pathway is found in more than half of all human cancers. Therefore, CDK4 is an attractive target for the development of a novel anticancer agent. However, it is difficult to make CDK4-specific inhibitors that do not possess activity for other kinases, especially CDK2, because the CDK family has high structural homol. The three-dimensional structure of CDK2, particularly that bound with the inhibitor, has provided useful information for the synthesis of CDK2-specific inhibitors. The same approach used to make CDK4-specific inhibitors was hindered by the failure to obtain a crystal structure of CDK4. To overcome this problem, we synthesized a CDK4 mimic CDK2 protein in which the ATP binding pocket of CDK2 was replaced with that of CDK4. This CDK4 mimic CDK2 was crystallized both in the free and inhibitor-bound form. The structural information thus obtained was found to be useful for synthesis of a CDK4-specific inhibitor that does not have substantial CDK2 activity. Namely, the data suggest that CDK4 has addnl. space that will accommodate a large substituent such as the CDK4 selective inhibitor. Inhibitors designed to bind into this large cavity should be selective for CDK4 without having substantial CDK2 activity. This design principle was confirmed in the x-ray crystal structure of the CDK4 mimic CDK2 with a new CDK4 selective inhibitor bound.

IT **360068-25-3D**, complex with CDK4-CDK2 chimeric protein
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(crystallog. approach to identification of cyclin-dependent kinase 4-specific inhibitors)

RN 360068-25-3 CAPLUS
CN Urea, N-[5-(2-pyrrolidinyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 18 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 19 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:152682 CAPLUS
DOCUMENT NUMBER: 134:207809
TITLE: Preparation of spiroisoindolinepiperidines, spiroisoquinolinepiperidines, spiroisobenzofuranpiperidines, and related compounds as neuropeptide Y antagonists.
INVENTOR(S): Fukami, Takehiro; Kanatani, Akio; Ishihara, Akane; Ishii, Yasuyuki; Takahashi, Toshiyuki; Haga, Yuji; Sakamoto, Toshihiro; Itoh, Takahiro
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001014376	A1	20010301	WO 2000-JP5427	20000811
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000013423	A	20020507	BR 2000-13423	20000811
EP 1204663	A1	20020515	EP 2000-951971	20000811
EP 1204663	B1	20031029		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
TR 200200408	T2	20020621	TR 2002-200200408	20000811
EE 200200082	A	20030616	EE 2002-82	20000811
NZ 517057	A	20030829	NZ 2000-517057	20000811
AU 767229	B2	20031106	AU 2000-64762	20000811
AT 253064	E	20031115	AT 2000-951971	20000811
PT 1204663	T	20040227	PT 2000-951971	20000811
ES 2206287	T3	20040516	ES 2000-951971	20000811
JP 2002030086	A2	20020129	JP 2000-247145	20000817
JP 3411262	B2	20030526		
ZA 2002000734	A	20030128	ZA 2002-734	20020128
BG 106390	A	20021229	BG 2002-106390	20020206
NO 2002000814	A	20020415	NO 2002-814	20020219
HK 1043123	A1	20040130	HK 2002-104686	20020624
US 2003055251	A1	20030320	US 2002-226225	20020823
US 6649624	B2	20031118		
JP 2003104884	A2	20030409	JP 2002-271261	20020918
JP 3553560	B2	20040811		
US 2003220499	A1	20031127	US 2003-453737	20030604
US 6723847	B2	20040420		

PRIORITY APPLN. INFO.:

JP 1999-233573	A	19990820
JP 2000-137692	A	20000510
WO 2000-JP5427	W	20000811
JP 2000-247145	A3	20000817
US 2000-640784	A3	20000818
US 2001-983598	A3	20011025
US 2002-101221	A3	20020320
US 2002-226225	A3	20020823

L6 ANSWER 19 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
OTHER SOURCE(S): MARPAT 134:207809
GI



I

AB Title compds. [I; Ar1 = (substituted) aryl, heteroaryl, QAr2; Ar2 = (substituted) aryl, heteroaryl; Q = bond, CO; T, U, V, W = N, (substituted) CH; X = N, CH; Y = (substituted) imino], were prepared Thus, N-tert-butoxycarbonyl-4-piperidone was refluxed 3 h with PhCH2NH2 in PhMe to give a residue which was stirred with o-iodobenzoyl chloride and Et3N in PhMe at 80° for 2 h to give N-benzyl-N-(1-tert-butoxycarbonyl-1,2,3,6-tetrahydropyridin-4-yl)-2-iodobenzamide. The latter was heated with Pd(OAc)2, Ph3P, K2CO3, and Et4NCl in MeCN at 80° for 6 h to give 2-benzyl-1'-tert-butoxycarbonyl-1',6'-dihydrospiro[1H-isoindole-1,4'(5'H)-pyridine]-3(2H)-one. This was converted to N-(4-benzoylphenyl)-3-oxospiro[isoindoline-1,4'-piperidine]-1'-carboxamide, (II), which inhibited [125I]peptide YY binding to NPY Y5 receptors with IC50 = 1.2 nM. II drug formulations are given.

IT **328232-23-1P 328232-24-2P 328232-25-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of spiroisoindolinepiperidines, spiroisoquinolinepiperidines, spiroisobenzofuranpiperidines, and related compds. as neuropeptide Y antagonists)

RN 328232-23-1 CAPLUS
CN Spiro[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide, 3-oxo-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 19 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 328232-24-2 CAPLUS
CN Spiro[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide, N-[5-(3-chlorophenyl)-1H-pyrazol-3-yl]-3-oxo- (9CI) (CA INDEX NAME)



RN 328232-25-3 CAPLUS
CN Spiro[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide, 3-oxo-N-[5-(3-quinolinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

L6 ANSWER 19 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 20 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:137023 CAPLUS
DOCUMENT NUMBER: 134:178552
TITLE: 3(5)-Acylaminopyrazole derivatives, process for their preparation and their use as antitumor agents
INVENTOR(S): Pevarello, Paolo; Orsini, Paolo; Traquandi, Gabriella; Varasi, Mario; Fritzen, Edward L.; Warpehoski, Martha A.; Pierce, Betsy S.; Brasca, Maria Grabriella
PATENT ASSIGNEE(S): Pharmacia & Upjohn S.p.A., Italy; Pharmacia & Upjohn Company
SOURCE: PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012189	A1	20010222	WO 2000-US6699	20000505
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000049714	A5	20010313	AU 2000-49714	20000505
EP 1202733	A1	20020508	EP 2000-931906	20000505
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000013143	A	20020611	BR 2000-13143	20000505
JP 2003507329	T2	20030225	JP 2001-516535	20000505
EE 200200065	A	20030415	EE 2002-65	20000505
NZ 517237	A	20040227	NZ 2000-517237	20000505
US 6218418	B1	20010417	US 2000-667603	20000922
NO 2002000684	A	20020403	NO 2002-684	20020211
HR 2002000128	A1	20030430	HR 2002-128	20020212
ZA 2002001511	A	20030311	ZA 2002-1511	20020222
BG 106480	A	20020930	BG 2002-106480	20020305
PRIORITY APPLN. INFO.:			US 1999-372831	A 19990812
			US 2000-560400	A1 20000428
			WO 2000-US6699	W 20000505

OTHER SOURCE(S): MARPAT 134:178552
GI



I

AB Compds. which are 3-acylaminopyrazole derivs. (I; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-2,2-diphenylacetamide) wherein R is C3-C6 cycloalkyl group optionally substituted by a straight or branched C1-C6 alkyl or arylalkyl group; R1 is a straight or branched C1-C6 alkyl, C2-C4 alkenyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, arylalkyl, arylcarbonyl, aryloxyalkyl or arylalkenyl group, each of which may be

=> d fide can l20

L20 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **256529-50-7** REGISTRY
ED Entered STN: 24 Feb 2000
CN Urea, N-ethyl-N'-[5-[4-phenyl-5-(trifluoromethyl)-2-thienyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H15 F3 N4 O S
SR CAS Client Services

Ring System Data

Elemental Analysis EA	Elemental Sequence ES	Size of the Rings SZ	Ring System Formula RF	Ring Identifier RID	RID Occurrence Count
C4S	SC4	5	C4S	16.145.3	1
C3N2	N2C3	5	C3N2	16.165.13	1
C6	C6	6	C6	46.150.18	1



Calculated Properties (CALC)

PROPERTY (CODE)	VALUE	CONDITION	NOTE
Bioconc. Factor (BCF)	108	pH 1	(1) ACD
Bioconc. Factor (BCF)	16837	pH 4	(1) ACD
Bioconc. Factor (BCF)	19986	pH 7	(1) ACD
Bioconc. Factor (BCF)	19989	pH 8	(1) ACD
Bioconc. Factor (BCF)	19963	pH 10	(1) ACD
Boiling Point (BP)	510.8+/-50.0 deg C	760.0 Torr	(1) ACD
Enthalpy of Vap. (HVAP)	78.16+/-3.0 kJ/mol		(1) ACD
Flash Point (FP)	262.7+/-54.2 deg C		(1) ACD
Freely Rotatable Bonds (FRB)	6		(1) ACD
H acceptors (HAC)	5		(1) ACD
H donors (HD)	3		(1) ACD
Koc (KOC)	225	pH 1	(1) ACD
Koc (KOC)	35098	pH 4	(1) ACD
Koc (KOC)	41662	pH 7	(1) ACD
Koc (KOC)	41669	pH 8	(1) ACD
Koc (KOC)	41614	pH 10	(1) ACD
logD (LOGD)	3.69	pH 1	(1) ACD
logD (LOGD)	5.89	pH 4	(1) ACD
logD (LOGD)	5.96	pH 7	(1) ACD
logD (LOGD)	5.96	pH 8	(1) ACD
logD (LOGD)	5.96	pH 10	(1) ACD
logP (LOGP)	5.963+/-0.571		(1) ACD
Molar Solubility (SLB.MOL)	<0.01 mol/L	pH 1	(1) ACD

Molar Solubility (SLB.MOL)	<0.01 mol/L	pH 4	(1) ACD
Molar Solubility (SLB.MOL)	<0.01 mol/L	pH 7	(1) ACD
Molar Solubility (SLB.MOL)	<0.01 mol/L	pH 8	(1) ACD
Molar Solubility (SLB.MOL)	<0.01 mol/L	pH 10	(1) ACD
Molecular Weight (MW)	380.39		(1) ACD
pKa (PKA)	12.94+/-0.10	Most Acidic	(1) ACD
pKa (PKA)	3.17+/-0.50	Most Basic	(1) ACD
Vapor Pressure (VP)	1.51E-10 Torr	25.0 deg C	(1) ACD

(1) Calculated using Advanced Chemistry Development (ACD/Labs) Software Solaris V4.76 ((C) 1994-2004 ACD/Labs)

See HELP PROPERTIES for information about property data sources in REGISTRY.

ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **256529-50-7** REGISTRY
CN Urea, N-ethyl-N'-[5-[4-phenyl-5-(trifluoromethyl)-2-thienyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H15 F3 N4 O S
SR CAS Client Services



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

optionally further substituted as indicated in the description; or a pharmaceutically acceptable salt thereof, processes for their preparation and their therapeutic uses. The compds. are useful for the treatment of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative diseases, but no quant. test results are presented. The cancer is selected from carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system, melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, thyroid follicular cancer and Kaposi's sarcoma. The cell proliferative disorder is selected from benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis. The method of treatment provides tumor angiogenesis and metastasis inhibition, cell cycle inhibition or cdk/cyclin dependent inhibition, and treatment or prevention of radiotherapy-induced or chemotherapy-induced alopecia. A process for preparing the 3-aminopyrazole derivative or the pharmaceutically acceptable salt thereof, comprising: (a) reacting RCO2R2 (R2 = alkyl), with MeCN in the presence of a basic agent, to obtain RC(O)CH2CN; (b) reacting RC(O)CH2CN with hydrazine hydrate to obtain an 3-amino-5-R-1H-pyrazole; (c) oxidizing the 3-amino-5-R-1H-pyrazole to obtain the nitro analog; (d) reacting the nitro compound with tert-butoxycarbonyl anhydride (Boc2O) to obtain the N-Boc derivative; (e) reducing this BOC derivative to obtain the amino analog; (f) reacting this amino compound with R1C(O)X (X = OH or a suitable leaving group) to obtain the N1-Boc-protected I; and (g) hydrolyzing this intermediate in an acidic medium to obtain I. Other methods of preparation are also claimed.

IT **326824-37-7P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-4-morpholinocarboxamide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(acylaminopyrazole derivs., process for preparation and use as antitumor agents)

RN 326824-37-7 CAPLUS

CN 4-Morpholinecarboxamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:137022 CAPLUS
DOCUMENT NUMBER: 134:193431
TITLE: 3(5)-Ureidopyrazole derivatives, processes for their preparation and their therapeutic uses including antitumor agents
INVENTOR(S): Pevarello, Paolo; Orsini, Paolo; Traquandi, Gabriella; Varasi, Mario; Fritzen, Edward L.; Warpehoski, Martha A.; Pierce, Betsy S.
PATENT ASSIGNEE(S): Pharmacia & Upjohn S.p.A., Italy; Pharmacia & Upjohn Company
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012188	A1	20010222	WO 2000-US17878	20000811
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6387900	B1	20020514	US 1999-372833	19990812
AU 2000067470	A5	20010313	AU 2000-67470	20000811
EP 1202734	A1	20020508	EP 2000-955241	20000811
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000013277	A	20020618	BR 2000-13277	20000811
JP 2003507328	T2	20030225	JP 2001-516534	20000811
NZ 517238	A	20040130	NZ 2000-517238	20000811
ZA 2002001118	A	20030310	ZA 2002-1118	20020208
NO 2002000687	A	20020403	NO 2002-687	20020211
PRIORITY APPLN. INFO.:			US 1999-372833 A	19990812
			WO 2000-US17878 W	20000811

OTHER SOURCE(S): MARPAT 134:193431
GI



I

AB Compds. which are 3(5)-ureidopyrazole derivs. (I; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[2-(1-piperidinyl)ethyl]urea) or a

pharmaceutically acceptable salt thereof, processes for their preparation and their use as antitumor agents are claimed. In I: R = C1-C6 alkyl, aryl or arylalkyl group, which is optionally substituted with ≥1 OH, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulfonyl, alkylsulfonylamino, aminosulfonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulfonyl, arylamino, arylcarbonyl, N-alkylpiperazinyl, 4-morpholinyl, perfluorinated C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C2-C4 aminoalkynyl or C2-C4 hydroxyalkynyl substituents. R1 = -(CH2)n-R3. N = 0-4. R3 = H, OH, amino, cycloalkyl, aryl and heterocyclyl, which is optionally substituted with ≥1 OH, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulfonyl, alkylsulfonylamino, aminosulfonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulfonyl, arylamino, arylcarbonyl, N-alkylpiperazinyl, 4-morpholinyl, perfluorinated C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C2-C4 aminoalkynyl or C2-C4 hydroxyalkynyl substituents. R2 = H, or R2 and R1, together with the N atom to which they are bonded, form a heterocyclyl or heteroaryl group, which is optionally substituted with ≥1 OH, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulfonyl, alkylsulfonylamino, aminosulfonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulfonyl, arylamino, arylcarbonyl, N-alkylpiperazinyl, 4-morpholinyl, perfluorinated C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C2-C4 aminoalkynyl or C2-C4 hydroxyalkynyl substituents. When n is 0 and R2 is H, R is a C3-C6 cycloalkyl group optionally substituted with a straight or branched C1-C6 alkyl group. The compds. are useful for the treatment of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative diseases, but no quant. test results are presented. The cancer is selected from carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system, melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, thyroid follicular cancer and Kaposi's sarcoma. The cell proliferative disorder is selected from benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis. The method of treatment provides tumor angiogenesis and metastasis inhibition, cell cycle inhibition or cdk/cyclin dependent inhibition, and treatment or prevention of radiotherapy-induced or chemotherapy-induced alopecia. A process for preparing I comprises : (a) reacting a 3-amino-5-R-1H-pyrazole with a R1NCO to produce a 1-R1NHC(O)-3-R1NHC(O)NH-5-R-1H-pyrazole and (b) selectively hydrolyzing this intermediate in a basic medium to produce I. Another method comprises (c) reacting a 1-tert-butoxycarbonyl-3-amino-5-R-1H-pyrazole with 4-nitrophenyl chloroformate, or a polymer supported form of 4-nitrophenyl chloroformate, to produce a 1-tert-butoxycarbonyl-3-(4-nitrophenoxycarbonylamino)-5-R-1H-pyrazole, or a polymer supported form; (d) reacting this intermediate with a R1R2NH to produce a 1-tert-butoxycarbonyl-3-(R1R2NC(O)NH)-5-R-1H-pyrazole; (e) hydrolyzing this compound in acidic medium to produce I; and,

optionally, converting the 3-ureidopyrazole derivative into another derivative, and/or into a salt thereof.

IT **326824-37-7P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-4-morpholinecarboxamide **326919-80-6P**, N-(5-Cyclopropyl-1H-pyrazol

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
3-yl)-N'-[2-(1-piperidinyl)ethyl]urea **326919-81-7P**, 4-[[[[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]carbonyl]amino]methyl]benzenesulfonamide **326919-83-9P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-[2-(1-pyrrolidinyl)ethyl]urea **326919-84-0P**, N-(3-Chlorophenethyl)-N'-(5-cyclopropyl-1H-pyrazol-3-yl)urea **326919-86-2P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(2,3-dimethoxybenzyl)urea **326919-87-3P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(4-chlorobenzyl)urea **326919-88-4P**, N-(5-tert-Butyl-1H-pyrazol-3-yl)-N'-(4-piperidinylmethyl)urea **326919-90-8P**, N-(5-tert-Butyl-1H-pyrazol-3-yl)-N'-(3-fluorobenzyl)urea **326919-91-9P**, N-(5-tert-Butyl-1H-pyrazol-3-yl)-N'-(3,4-dimethoxybenzyl)urea **326919-92-0P**, N-(5-tert-Butyl-1H-pyrazol-3-yl)-N'-(4-chlorobenzyl)urea **326919-93-1P**, N-(5-tert-Butyl-1H-pyrazol-3-yl)-N'-(3,4-dihydroxybenzyl)urea **326919-94-2P**, N-(5-tert-Butyl-1H-pyrazol-3-yl)-N'-(3-chlorophenethyl)urea **326919-95-3P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(4-piperidinylmethyl)urea **326919-96-4P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(3-fluorobenzyl)urea **326919-97-5P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(3,4-dimethoxybenzyl)urea **326919-98-6P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(3,4-dimethylbenzyl)urea **326919-99-7P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(2-hydroxy-1-methyl-2-phenylethyl)urea **326920-00-7P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-[(1-ethyl-2-pyrrolidinyl)methyl]urea **326920-01-8P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-[2-(2H-imidazol-4-yl)ethyl]urea **326920-03-0P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-[2-(5-methoxy-1H-indol-3-yl)ethyl]urea **326920-04-1P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(1H-indol-6-yl)urea **326920-05-2P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(1,3-benzodioxol-5-ylmethyl)urea **326920-06-3P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-[2-(4-morpholinyl)ethyl]urea **326920-07-4P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(2-chlorobenzyl)urea **326920-08-5P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(2,4-dichlorobenzyl)urea **326920-09-6P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(2-ethoxybenzyl)urea **326920-10-9P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(3,4-dichlorobenzyl)urea **326920-11-0P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(3-methoxybenzyl)urea **326920-12-1P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(4-fluorobenzyl)urea **326920-13-2P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(3-trifluoromethylbenzyl)urea **326920-14-3P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(4-methylbenzyl)urea **326920-15-4P**, N-(5-Cyclopentyl-1H-pyrazol-3-yl)-1-piperazinecarboxamide **326920-16-5P**, N-(5-Cyclopentyl-1H-pyrazol-3-yl)-4-phenyl-1-piperazinecarboxamide **326920-17-6P**, N-(5-Cyclopentyl-1H-pyrazol-3-yl)-4-methyl-1-piperazinecarboxamide **326920-18-7P**, N-(5-Cyclopentyl-1H-pyrazol-3-yl)-4-benzyl-1-piperazinecarboxamide **326920-19-8P**, N-(5-Cyclopentyl-1H-pyrazol-3-yl)-4-morpholinecarboxamide **326920-20-1P**, N-(5-Cyclopentyl-1H-pyrazol-3-yl)-1-piperidinecarboxamide **326920-21-2P**, N-(5-Cyclopentyl-1H-pyrazol-3-yl)-4-(aminomethyl)-1-piperidinecarboxamide **326920-22-3P**, N-(5-Cyclopentyl-1H-pyrazol-3-yl)-N'-benzylurea **326920-23-4P**, N-(5-Cyclopentyl-1H-pyrazol-3-yl)-N'-phenethylurea **326920-25-6P**, N-(5-Cyclopentyl-1H-pyrazol-3-yl)-N'-(3,4-dimethoxyphenethyl)urea **326920-27-8P**, N-(5-Cyclopentyl-1H-pyrazol-3-yl)-N'-(4-hydroxyphenethyl)urea **326920-29-0P**, N-(5-Cyclopentyl-1H-pyrazol-3-yl)-N'-propylurea **326920-31-4P**, N-(5-Cyclopentyl-1H-pyrazol-3-yl)-4-[2-nitro-4-(trifluoromethyl)phenyl]-1-piperazinecarboxamide **326920-32-5P**, N-(5-Phenethyl-1H-pyrazol-3-

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
yl)-1-pyrrolidinecarboxamide **326920-33-6P**, 4-(1,3-Benzodioxol-5-ylmethyl)-N-(5-phenethyl-1H-pyrazol-3-yl)-1-piperazinecarboxamide **326920-34-7P**, N-(5-Phenethyl-1H-pyrazol-3-yl)-1-piperazinecarboxamide **326920-35-8P**, N-(5-Phenethyl-1H-pyrazol-3-yl)-4-phenyl-1-piperazinecarboxamide **326920-36-9P**, N-(5-Phenethyl-1H-pyrazol-3-yl)-4-methyl-1-piperazinecarboxamide **326920-37-0P**, N-(5-Phenethyl-1H-pyrazol-3-yl)-4-benzyl-1-piperazinecarboxamide **326920-38-1P**, N-(5-Phenethyl-1H-pyrazol-3-yl)-4-morpholinecarboxamide **326920-40-5P**, N-(5-Phenethyl-1H-pyrazol-3-yl)-1-piperidinecarboxamide **326920-42-7P**, N-(5-Phenethyl-1H-pyrazol-3-yl)-4-(aminomethyl)-1-piperidinecarboxamide **326920-43-8P**, N-(5-Phenethyl-1H-pyrazol-3-yl)-N'-phenethylurea **326920-45-0P**, N-(5-Phenethyl-1H-pyrazol-3-yl)-N'-(3,4-dimethoxyphenethyl)urea **326920-47-2P**, N-(5-Phenethyl-1H-pyrazol-3-yl)-N'-(4-hydroxyphenethyl)urea **326920-48-3P**, N-(5-Phenethyl-1H-pyrazol-3-yl)-N'-propylurea **326920-50-7P**, N-(5-Phenethyl-1H-pyrazol-3-yl)-4-[2-nitro-4-(trifluoromethyl)phenyl]-1-piperazinecarboxamide **326920-51-8P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-butylurea **326920-52-9P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(2,4-dimethylphenyl)urea **326920-53-0P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(3,4-dimethoxyphenyl)urea **326920-54-1P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(3-carboxyphenyl)urea **326920-56-3P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(2,3-dimethylphenyl)urea **326920-58-5P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(3-carboxy-4-chlorophenyl)urea **326920-60-9P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(3,5-dimethylphenyl)urea **326920-61-0P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(3-carboxamidophenyl)urea **326920-63-2P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(3-carboxy-4-hydroxyphenyl)urea **326920-65-4P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(2,6-dimethylphenyl)urea **326920-66-5P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(4-cyanophenyl)urea **326920-68-7P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(3-acetylphenyl)urea **326920-70-1P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(1H-benzimidazol-6-yl)urea **326920-72-3P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(4-hydroxy-3-methoxybenzyl)urea **326920-73-4P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-benzylurea **326920-75-6P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-[3-[3-(dimethylamino)-1-propynyl]phenyl]urea **326920-77-8P**, N-[3-[[[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]carbonyl]amino]phenyl]methanesulfonamide **326920-78-9P**, 2-[3-[[[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]carbonyl]amino]anilino]acetamide **326920-79-0P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(2-hydroxyphenyl)urea **326920-80-3P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-[3-(3-hydroxy-1-butynyl)phenyl]urea **326920-81-4P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(1H-indol-5-yl)urea **326920-83-6P**, 4-[[[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]carbonyl]amino]benzenesulfonamide **326920-84-7P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(3-methoxyphenyl)urea **326920-85-8P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-phenylurea **326920-86-9P**, N-[4-[[[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]carbonyl]amino]phenyl]-N-methylacetamide **326920-87-0P**, N-[2-[[Cyclohexyl(methyl)amino]methyl]phenyl]-N'-(5-cyclopropyl-1H-pyrazol-3-yl)urea **326920-88-1P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(2-methoxyphenyl)urea **326920-90-5P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(2-chlorophenyl)urea **326920-91-6P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(3-ethynylphenyl)urea **326920-92-7P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(4-aminophenyl)urea

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
326920-93-8P, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(3-hydroxy-4-methylphenyl)urea **326920-94-9P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-3-oxo-3,4-dihydro-1(2H)-quinoxalinecarboxamide **326920-96-1P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(4-pyridinylmethyl)urea **326920-97-2P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(2-furylmethyl)urea **326920-98-3P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(1,3-benzothiazol-5-yl)urea **326920-99-4P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(1,3-dimethyl-1H-pyrazol-5-yl)urea **326921-00-0P**, N-[5-[[[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]carbonyl]amino]-2-methoxyphenyl]acetamide **326921-01-1P**, N-[3-[[[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]carbonyl]amino]-4-methoxyphenyl]acetamide **326921-03-3P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(3-aminophenyl)urea **326921-04-4P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(3-hydroxyphenyl)urea **326921-05-5P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-(4-hydroxyphenyl)urea **326921-06-6P**, N-(5-tert-Butyl-1H-pyrazol-3-yl)-N'-(3,4-dimethylbenzyl)urea **326921-07-7P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-3,4-dihydro-2(1H)-isoquinolinecarboxamide **326921-09-9P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-[2-(5-methoxy-2H-indol-3-yl)ethyl]urea **326921-10-2P**, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-[2-(2-pyridinyl)ethyl]urea **326921-11-3P**, N-(5-Cyclopentyl-1H-pyrazol-3-yl)-N'-(4-hydroxybutyl)urea **326921-12-4P**, N-(5-Cyclopentyl-1H-pyrazol-3-yl)-N'-(1-benzyl-4-piperidinyl)urea **326921-13-5P**, 4-(1,3-Benzodioxol-5-ylmethyl)-N-(5-cyclopentyl-1H-pyrazol-3-yl)-1-piperazinecarboxamide **326921-14-6P**, N-Cyclobutyl-N'-(5-cyclopentyl-1H-pyrazol-3-yl)urea **326921-15-7P**, N-(5-Cyclopentyl-1H-pyrazol-3-yl)-1-pyrrolidinecarboxamide **326921-16-8P**, N-Cyclobutyl-N'-(5-phenethyl-1H-pyrazol-3-yl)urea **326921-17-9P**, N-(5-Phenethyl-1H-pyrazol-3-yl)-N'-(1-benzyl-4-piperidinyl)urea **326921-18-0P**, N-(5-Phenethyl-1H-pyrazol-3-yl)-N'-benzylurea **326921-20-4P**, N-(5-Phenethyl-1H-pyrazol-3-yl)-N'-(4-hydroxybutyl)urea
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(ureidopyrazole derivs., processes for prepn. and therapeutic uses including antitumor agents)

RN 326824-37-7 CAPLUS
CN 4-Morpholinecarboxamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 326919-80-6 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[2-(1-piperidinyl)ethyl]- (9CI)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(CA INDEX NAME)



RN 326919-81-7 CAPLUS
CN Benzenesulfonamide, 4-[[[[(5-cyclopropyl-1H-pyrazol-3-yl)amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 326919-83-9 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326919-84-0 CAPLUS
CN Urea, N-[2-(3-chlorophenyl)ethyl]-N'-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 326919-86-2 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[(2,3-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326919-87-3 CAPLUS
CN Urea, N-[(4-chlorophenyl)methyl]-N'-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 326919-88-4 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326919-90-8 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-[(3-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 326919-91-9 CAPLUS
CN Urea, N-[(3,4-dimethoxyphenyl)methyl]-N'-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 326919-92-0 CAPLUS
CN Urea, N-[(4-chlorophenyl)methyl]-N'-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 326919-93-1 CAPLUS
CN Urea, N-[(3,4-dihydroxyphenyl)methyl]-N'-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326919-94-2 CAPLUS
CN Urea, N-[2-(3-chlorophenyl)ethyl]-N'-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 326919-95-3 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 326919-96-4 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[(3-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326919-97-5 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[(3,4-dimethoxyphenyl)methyl]-(9CI) (CA INDEX NAME)



RN 326919-98-6 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[(3,4-dimethylphenyl)methyl]-(9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326919-99-7 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-(2-hydroxy-1-methyl-2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 326920-00-7 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 326920-01-8 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[2-(2H-imidazol-4-yl)ethyl]-(9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-03-0 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 326920-04-1 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-1H-indol-6-yl- (9CI) (CA INDEX NAME)



RN 326920-05-2 CAPLUS
CN Urea, N-(1,3-benzodioxol-5-ylmethyl)-N'-(5-cyclopropyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)



RN 326920-06-3 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-07-4 CAPLUS
CN Urea, N-[(2-chlorophenyl)methyl]-N'-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 326920-08-5 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[(2,4-dichlorophenyl)methyl]-(9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-09-6 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[(2-ethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 326920-10-9 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-11-0 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 326920-12-1 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-13-2 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 326920-14-3 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-15-4 CAPLUS
CN 1-Piperazinecarboxamide, N-(5-cyclopentyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 326920-16-5 CAPLUS
CN 1-Piperazinecarboxamide, N-(5-cyclopentyl-1H-pyrazol-3-yl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 326920-17-6 CAPLUS
CN 1-Piperazinecarboxamide, N-(5-cyclopentyl-1H-pyrazol-3-yl)-4-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-18-7 CAPLUS
CN 1-Piperazinecarboxamide, N-(5-cyclopentyl-1H-pyrazol-3-yl)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 326920-19-8 CAPLUS
CN 4-Morpholinecarboxamide, N-(5-cyclopentyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 326920-20-1 CAPLUS
CN 1-Piperidinecarboxamide, N-(5-cyclopentyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-21-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-(aminomethyl)-N-(5-cyclopentyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 326920-22-3 CAPLUS
CN Urea, N-(5-cyclopentyl-1H-pyrazol-3-yl)-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 326920-23-4 CAPLUS
CN Urea, N-(5-cyclopentyl-1H-pyrazol-3-yl)-N'-(2-phenylethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-25-6 CAPLUS
CN Urea, N-(5-cyclopentyl-1H-pyrazol-3-yl)-N'-[2-(3,4-dimethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 326920-27-8 CAPLUS
CN Urea, N-(5-cyclopentyl-1H-pyrazol-3-yl)-N'-[2-(4-hydroxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-29-0 CAPLUS
CN Urea, N-(5-cyclopentyl-1H-pyrazol-3-yl)-N'-propyl- (9CI) (CA INDEX NAME)



RN 326920-31-4 CAPLUS
CN 1-Piperazinecarboxamide, N-(5-cyclopentyl-1H-pyrazol-3-yl)-4-[2-nitro-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-32-5 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[5-(2-phenylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 326920-33-6 CAPLUS
CN 1-Piperazinecarboxamide, 4-(1,3-benzodioxol-5-ylmethyl)-N-[5-(2-phenylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 326920-34-7 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-(2-phenylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-40-5 CAPLUS
CN 1-Piperidinecarboxamide, N-[5-(2-phenylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 326920-42-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-(aminomethyl)-N-[5-(2-phenylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 326920-43-8 CAPLUS
CN Urea, N-(2-phenylethyl)-N'-[5-(2-phenylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 326920-45-0 CAPLUS
CN Urea, N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-[5-(2-phenylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-35-8 CAPLUS
CN 1-Piperazinecarboxamide, 4-phenyl-N-[5-(2-phenylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 326920-36-9 CAPLUS
CN 1-Piperazinecarboxamide, 4-methyl-N-[5-(2-phenylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 326920-37-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-(2-phenylethyl)-1H-pyrazol-3-yl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 326920-38-1 CAPLUS
CN 4-Morpholinecarboxamide, N-[5-(2-phenylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-47-2 CAPLUS
CN Urea, N-[2-(4-hydroxyphenyl)ethyl]-N'-[5-(2-phenylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 326920-48-3 CAPLUS
CN Urea, N-[5-(2-phenylethyl)-1H-pyrazol-3-yl]-N'-propyl- (9CI) (CA INDEX NAME)



RN 326920-50-7 CAPLUS
CN 1-Piperazinecarboxamide, 4-[2-nitro-4-(trifluoromethyl)phenyl]-N-[5-(2-phenylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 326920-51-8 CAPLUS
CN Urea, N-butyl-N'-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-52-9 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 326920-53-0 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 326920-54-1 CAPLUS
CN Benzoic acid, 3-[[[(5-cyclopropyl-1H-pyrazol-3-yl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 326920-56-3 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-(2,3-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 326920-58-5 CAPLUS
CN Benzoic acid, 2-chloro-5-[[[(5-cyclopropyl-1H-pyrazol-3-yl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-60-9 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 326920-61-0 CAPLUS
CN Benzamide, 3-[[[(5-cyclopropyl-1H-pyrazol-3-yl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-63-2 CAPLUS
CN Benzoic acid, 5-[[[(5-cyclopropyl-1H-pyrazol-3-yl)amino]carbonyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 326920-65-4 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-66-5 CAPLUS
CN Urea, N-(4-cyanophenyl)-N'-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 326920-68-7 CAPLUS
CN Urea, N-(3-acetylphenyl)-N'-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-70-1 CAPLUS
CN Urea, N-1H-benzimidazol-5-yl-N'-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 326920-72-3 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[(4-hydroxy-3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-73-4 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 326920-75-6 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[3-[3-(dimethylamino)-1-propynyl]phenyl]- (9CI) (CA INDEX NAME)



RN 326920-77-8 CAPLUS
CN Methanesulfonamide, N-[3-[[[(5-cyclopropyl-1H-pyrazol-3-yl)amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-78-9 CAPLUS
CN Acetamide, 2-[[3-[[[(5-cyclopropyl-1H-pyrazol-3-yl)amino]carbonyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 326920-79-0 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-80-3 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[3-(3-hydroxy-1-butynyl)phenyl]- (9CI) (CA INDEX NAME)



RN 326920-81-4 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-1H-indol-5-yl- (9CI) (CA INDEX NAME)



RN 326920-83-6 CAPLUS
CN Benzenesulfonamide, 4-[[[(5-cyclopropyl-1H-pyrazol-3-

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-86-9 CAPLUS
CN Acetamide, N-[4-[[[(5-cyclopropyl-1H-pyrazol-3-yl)amino]carbonyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 326920-87-0 CAPLUS
CN Urea, N-[2-[(cyclohexylmethylamino)methyl]phenyl]-N'-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 326920-88-1 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
yl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 326920-84-7 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 326920-85-8 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-90-5 CAPLUS
CN Urea, N-(2-chlorophenyl)-N'-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 326920-91-6 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-(3-ethynylphenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-92-7 CAPLUS
CN Urea, N-(4-aminophenyl)-N'-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 326920-93-8 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-(3-hydroxy-4-methylphenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-97-2 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-(2-furanylmethyl)- (9CI) (CA INDEX NAME)



RN 326920-98-3 CAPLUS
CN Urea, N-5-benzothiazolyl-N'-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 326920-99-4 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-(1,3-dimethyl-1H-pyrazol-5-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326920-94-9 CAPLUS
CN 1(2H)-Quinoxalinecarboxamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)



RN 326920-96-1 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326921-00-0 CAPLUS
CN Acetamide, N-[5-[[[(5-cyclopropyl-1H-pyrazol-3-yl)amino]carbonyl]amino]-2-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 326921-01-1 CAPLUS
CN Acetamide, N-[3-[[[(5-cyclopropyl-1H-pyrazol-3-yl)amino]carbonyl]amino]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 326921-03-3 CAPLUS
CN Urea, N-(3-aminophenyl)-N'-(5-cyclopropyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326921-04-4 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 326921-05-5 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326921-06-6 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-[(3,4-dimethylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 326921-07-7 CAPLUS
CN 2(1H)-Isoquinolinecarboxamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 326921-09-9 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[2-(5-methoxy-2H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326921-10-2 CAPLUS
CN Urea, N-(5-cyclopropyl-1H-pyrazol-3-yl)-N'-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 326921-11-3 CAPLUS
CN Urea, N-(5-cyclopentyl-1H-pyrazol-3-yl)-N'-(4-hydroxybutyl)- (9CI) (CA INDEX NAME)



RN 326921-12-4 CAPLUS
CN Urea, N-(5-cyclopentyl-1H-pyrazol-3-yl)-N'-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326921-13-5 CAPLUS
CN 1-Piperazinecarboxamide, 4-(1,3-benzodioxol-5-ylmethyl)-N-(5-cyclopentyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 326921-14-6 CAPLUS
CN Urea, N-cyclobutyl-N'-(5-cyclopentyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 326921-15-7 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-(5-cyclopentyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 326921-16-8 CAPLUS
CN Urea, N-cyclobutyl-N'-[5-(2-phenylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 326921-17-9 CAPLUS
CN Urea, N-[5-(2-phenylethyl)-1H-pyrazol-3-yl]-N'-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 326921-18-0 CAPLUS
CN Urea, N-[5-(2-phenylethyl)-1H-pyrazol-3-yl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 326921-20-4 CAPLUS
CN Urea, N-(4-hydroxybutyl)-N'-[5-(2-phenylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:78363 CAPLUS
DOCUMENT NUMBER: 134:147614
TITLE: Preparation of N,N'-biarylurea derivatives as inhibitors of cyclin-dependent kinases (Cdk4 and Cdk6)
INVENTOR(S): Hayama, Takashi; Hayashi, Kyoko; Honma, Mitsutaka; Takahashi, Ikuko
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 460 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007411	A1	20010201	WO 2000-JP4991	20000726
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2001106673	A2	20010417	JP 2000-274175	20000726
EP 1199306	A1	20020424	EP 2000-949909	20000726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: JP 1999-211384 A 19990726
WO 2000-JP4991 W 20000726

OTHER SOURCE(S): MARPAT 134:147614
GI



I



II

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
AB N-(hetero)aryl-N'-heterocyclylurea derivs. represented by general formula (I) [wherein Ar represents a nitrogenous heterocyclic aromatic group such as (un)substituted pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyrrolyl, imidazolyl, indolyl, isoindolyl, quinolyl, isoquinolyl, benzothiazolyl, or benzoxazolyl; X and Z each represents C or N or together with R1 or R2 and/or R3 represent CH or N; Y represents CO, SO, or SO2; R1 represents hydrogen, (un)substituted lower alkyl, Y3-W2-Y4-R5, etc.; wherein R5 = H, (un)substituted lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl, imidazolyl, isoxazolyl, isoquinolyl, isoindolyl, indazolyl, indolyl, indolidinyl, isothiazolyl, ethylenedioxyphenyl, oxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, quinoxalinyl, quinolyl, etc.; W2 = ingle bond, O, S, SO, SO2, N-(un)substituted NH, SO2NH, NHSO2NH, NHSO2, CONH, NHCO, NHCONH, NHCO2, etc.; Y3, Y4 = single bond, linear or branched lower alkylene; R2 and R3 each represents hydrogen, lower alkyl or alkoxy, or Y3-W2-Y4-R5 (Y3, W2, Y4, R5 = same as above), or one of R2 and R3 together with R1 and X forms cyclohexane, cyclopentane, piperidine, 3,4,5,6-tetrahydro-1,3-oxazine, tetrahydrothiopyran, pyrrolidine, tetrahydrothiofuran, oxazolidine ring, etc.; R4 and R5 represent H, halo, OH, amino, or Y3-W2-Y4-R5 (Y3, W2, Y4, R5 = same as above)] or salts thereof are prepared The compds. (e.g. II) have a remarkable proliferation-inhibitory effect on tumor cells. A Cdk4 and/or Cdk6 inhibitor for use in the therapy of malignant tumor can hence be provided. II showed IC50 of 0.061 and 0.019 μM against cyclin-D1-Cdk4 and cyclin-D2-Cdk4, resp., vs. 0.36 and 0.056 μM, resp., for (±)-flavopiridol, and inhibited the proliferation of HCT116 and MKN-1 cells with IC50 of 0.013 and 0.10 μM, resp., vs. 0.15 and 0.87 μM, resp., for (±)-flavopiridol. Pharmaceutical formulations containing I were prepared
IT **322689-03-2P 322689-05-4P 322689-07-6P 322689-08-7P 322689-36-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(hetero)aryl-N'-heterocyclylurea derivs. as in inhibitors of cyclin-dependent kinases (Cdk4 and Cdk6) and antitumor agents)
RN 322689-03-2 CAPLUS
CN Urea, N-[5-[[[(2R)-5-chloro-2,3-dihydro-1H-inden-2-yl]amino]methyl]-1H-pyrazol-3-yl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-05-4 CAPLUS
CN Urea, N-[5-[[[(2R)-5-chloro-2,3-dihydro-1H-inden-2-yl]amino]methyl]-1H-pyrazol-3-yl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322689-07-6 CAPLUS
CN Urea, N-[5-[[[(2S)-5-chloro-2,3-dihydro-1H-inden-2-yl]amino]methyl]-1H-pyrazol-3-yl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **322688-49-3P 322688-51-7P 322688-53-9P**
322688-55-1P 322688-57-3P 322688-58-4P
322688-60-8P 322688-62-0P 322688-64-2P
322688-65-3P 322688-67-5P 322688-68-6P
322688-69-7P 322688-70-0P 322688-72-2P
322688-73-3P 322688-74-4P 322688-75-5P
322688-76-6P 322688-78-8P 322688-79-9P
322688-80-2P 322688-81-3P 322688-82-4P
322688-84-6P 322688-85-7P 322688-87-9P
322688-89-1P 322688-90-4P 322688-91-5P
322688-92-6P 322688-93-7P 322688-95-9P
322688-96-0P 322688-97-1P 322688-98-2P
322689-00-9P 322689-01-0P 322689-09-8P
322689-20-3P 322689-21-4P 322689-22-5P
322689-29-2P 322689-30-5P 322689-34-9P
322689-35-0P 322689-40-7P 322689-46-3P
322689-47-4P 322689-49-6P 322689-50-9P
322689-51-0P 322689-52-1P 322689-53-2P
322689-54-3P 322689-55-4P 322689-56-5P
322689-57-6P 322689-58-7P 322689-59-8P
322689-60-1P 322689-71-4P 322689-72-5P
322689-73-6P 322689-74-7P 322689-75-8P
322689-76-9P 322689-77-0P 322689-78-1P
322689-79-2P 322689-80-5P 322689-81-6P
322689-82-7P 322689-83-8P 322689-84-9P
322689-85-0P 322689-86-1P 322689-87-2P
322689-88-3P 322689-89-4P 322689-90-7P
322689-91-8P 322689-92-9P 322689-93-0P
322689-94-1P 322689-95-2P 322689-96-3P
322689-97-4P 322689-98-5P 322689-99-6P
322690-00-6P 322690-01-7P 322690-03-9P
322690-04-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(hetero)aryl-N'-heterocyclylurea derivs. as in inhibitors
of cyclin-dependent kinases (Cdk4 and Cdk6) and antitumor agents)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-08-7 CAPLUS
CN Urea, N-[5-[[(1,1-dimethylethyl)methylamino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-36-1 CAPLUS
CN Urea, N-[5-[(3S)-5-oxo-1-(phenylmethyl)-3-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 322688-49-3 CAPLUS
CN Urea, N-[5-[[(2-methylphenyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 322688-51-7 CAPLUS
CN Urea, N-[5-[[(3-methylphenyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 322688-53-9 CAPLUS
CN Urea, N-[5-[[(4-methylphenyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 322688-55-1 CAPLUS
CN Urea, N-[5-[[[2-(1-methylethyl)phenyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 322688-57-3 CAPLUS
CN Urea, N-[5-[[[3-(1-methylethyl)phenyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 322688-58-4 CAPLUS
CN Urea, N-[5-[[[4-(1-methylethyl)phenyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 322688-60-8 CAPLUS
CN Urea, N-[5-[[(2,3-dihydro-1H-inden-1-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 322688-62-0 CAPLUS
CN Urea, N-[5-[[(1-phenylethyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-64-2 CAPLUS
CN Urea, N-[5-[[(1-methylheptyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-65-3 CAPLUS
CN Urea, N-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)-N'-[5-[[(1,1,3,3-tetramethylbutyl)amino]methyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-67-5 CAPLUS
CN Urea, N-[5-[[(2,3-dihydro-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-68-6 CAPLUS
CN Urea, N-[5-[[[(1R)-1-(hydroxymethyl)-2-phenylethyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-69-7 CAPLUS
CN Urea, N-[5-[[[1-(hydroxymethyl)propyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-70-0 CAPLUS
CN Urea, N-[5-[[(2-hydroxy-1,1-dimethylethyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-72-2 CAPLUS
CN Urea, N-[5-[[[(1R,2S)-2-hydroxy-1-(methoxymethyl)-2-phenylethyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322688-73-3 CAPLUS
CN Urea, N-[5-[[(hexahydro-2-oxo-1H-azepin-3-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 322688-74-4 CAPLUS
CN Urea, N-[5-[(cyclododecylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 322688-75-5 CAPLUS
CN Urea, N-[5-[[[1-(hydroxymethyl)cyclopentyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 322688-76-6 CAPLUS
CN Urea, N-[5-[[[(1R)-1-(hydroxymethyl)-2,2-dimethylpropyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A



RN 322688-79-9 CAPLUS
CN Urea, N-[5-[(1-azabicyclo[2.2.2]oct-3-ylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-80-2 CAPLUS
CN Urea, N-[5-[[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-78-8 CAPLUS
CN Urea, N-[5-[[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-81-3 CAPLUS
CN Urea, N-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)-N'-[5-[[[1-(3-thienylmethyl)-4-piperidinyl]amino]methyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A



RN 322688-82-4 CAPLUS
CN Urea, N-[5-[[(2,3-dihydro-5,6-dimethoxy-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-84-6 CAPLUS
CN Urea, N-[5-[[(5-chloro-2,3-dihydro-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-85-7 CAPLUS
CN Urea, N-[5-[[(2,3-dihydro-4-methoxy-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-87-9 CAPLUS
CN Urea, N-[5-[[(2,3-dihydro-5-methoxy-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-89-1 CAPLUS
CN Urea, N-[5-[[(2,3-dihydro-4,5-dimethoxy-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-90-4 CAPLUS
CN Urea, N-[5-[[(7-ethyl-2,3-dihydro-4,5-dimethoxy-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-91-5 CAPLUS
CN Urea, N-[5-[[(2,3-dihydro-5-methyl-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-92-6 CAPLUS
CN Urea, N-[5-[[(5-fluoro-2,3-dihydro-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-93-7 CAPLUS
CN Urea, N-[5-[[(5-bromo-2,3-dihydro-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-95-9 CAPLUS
CN Urea, N-[5-[[(4-chloro-2,3-dihydro-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-98-2 CAPLUS
CN Urea, N-[5-[[(2,3-dihydro-1H-benz[f]inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-00-9 CAPLUS
CN Urea, N-[5-[[(2,3-dihydro-1H-benz[e]inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-96-0 CAPLUS
CN Urea, N-[5-[[(5,6-dichloro-2,3-dihydro-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-97-1 CAPLUS
CN Urea, N-[5-[[(2,3-dihydro-2-methyl-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-01-0 CAPLUS
CN Urea, N-[5-[[[(2S)-5-chloro-2,3-dihydro-1H-inden-2-yl]amino]methyl]-1H-pyrazol-3-yl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322689-09-8 CAPLUS
CN Urea, N-[5-[[(5-chloro-2,3-dihydro-1H-inden-2-yl)methylamino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-20-3 CAPLUS
CN Urea, N-[5-(6-methyl-2-pyridinyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-21-4 CAPLUS
CN Urea, N-[5-(1-naphthalenyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-30-5 CAPLUS
CN Urea, N-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)-N'-[5-(2-thienyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 322689-34-9 CAPLUS
CN Urea, N-[5-[(2S,4R)-4-hydroxy-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-22-5 CAPLUS
CN Urea, N-[5-(3-methylphenyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-29-2 CAPLUS
CN Urea, N-[5-[5-methyl-1-(phenylmethyl)-1H-imidazol-4-yl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-35-0 CAPLUS
CN Urea, N-[5-[(2S,4R)-4-hydroxy-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322689-40-7 CAPLUS
CN Urea, N-[5-[(2S)-5-oxo-1-(phenylmethyl)-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-46-3 CAPLUS
CN Urea, N-[5-[(2S)-1-methyl-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322689-47-4 CAPLUS
CN Urea, N-[5-[(2S)-1-methyl-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

RN 322689-50-9 CAPLUS
CN Urea, N-(5-acetyl-1H-pyrazol-3-yl)-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-51-0 CAPLUS
CN Urea, N-[5-[1-(phenylmethoxy)ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-49-6 CAPLUS
CN Urea, N-[5-[1-(cyclohexylamino)ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 322689-52-1 CAPLUS
CN Urea, N-[5-[1-[(phenylmethyl)amino]ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-53-2 CAPLUS
CN Urea, N-[5-(1-hydroxyethyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-54-3 CAPLUS
CN Urea, N-[5-[1-(ethylamino)ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-55-4 CAPLUS
CN Urea, N-[5-[1-(propylamino)ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-56-5 CAPLUS
CN Urea, N-[5-[1-[[(1R)-1-phenylethyl]amino]ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

RN 322689-58-7 CAPLUS
CN Urea, N-[5-[1-(cyclopropylamino)ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 322689-59-8 CAPLUS
CN Urea, N-[5-[1-[(1-methylethyl)amino]ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-57-6 CAPLUS
CN Urea, N-[5-[1-(cyclopentylamino)ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-60-1 CAPLUS
CN Urea, N-[5-[1-(1-piperidinyl)ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

RN 322689-71-4 CAPLUS
CN Urea, N-[5-[(butylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-72-5 CAPLUS
CN Urea, N-[5-[(cyclohexylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 322689-73-6 CAPLUS
CN Urea, N-[5-[[(phenylmethyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-74-7 CAPLUS
CN Urea, N-[5-[(propylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-75-8 CAPLUS
CN Urea, N-[5-[[(1-methylethyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-76-9 CAPLUS
CN Urea, N-[5-[[(1,1-dimethylethyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-77-0 CAPLUS
CN Urea, N-[5-[(dimethylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-78-1 CAPLUS
CN Urea, N-[5-(1-piperidinylmethyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

RN 322689-79-2 CAPLUS
CN Urea, N-[5-(1-pyrrolidinylmethyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-80-5 CAPLUS
CN Urea, N-[5-[(methylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-81-6 CAPLUS
CN Urea, N-[5-[(cycloheptylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

RN 322689-82-7 CAPLUS
CN Urea, N-[5-[(cyclopentylamino)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 322689-83-8 CAPLUS
CN Urea, N-[5-[[(1-methylpropyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-84-9 CAPLUS
CN Urea, N-[5-[[(1-methylbutyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-85-0 CAPLUS
CN Urea, N-[5-[[(1-methylpentyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-88-3 CAPLUS
CN Urea, N-[5-[[(1,3-dimethylbutyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-89-4 CAPLUS
CN Urea, N-[5-[[(1,2-dimethylpropyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-86-1 CAPLUS
CN Urea, N-[5-[[(1-methylhexyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-87-2 CAPLUS
CN Urea, N-[5-[[(1,4-dimethylpentyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-90-7 CAPLUS
CN Urea, N-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)-N'-[5-[[(1,2,2-trimethylpropyl)amino]methyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 322689-91-8 CAPLUS
CN Urea, N-[5-[[(1-methyl-1-phenylethyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-92-9 CAPLUS
CN Urea, N-[5-[[[(1R)-1-(4-methylphenyl)ethyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322689-93-0 CAPLUS
CN Urea, N-[5-[[[(1S)-1-(4-methylphenyl)ethyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-96-3 CAPLUS
CN Urea, N-[5-[[[(1R)-1-cyclohexylethyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322689-97-4 CAPLUS
CN Urea, N-[5-[[[4-(diethylamino)-1-methylbutyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-94-1 CAPLUS
CN Urea, N-[5-[[[(1R)-1-(1-naphthalenyl)ethyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322689-95-2 CAPLUS
CN Urea, N-[5-[[[(1S)-1-(1-naphthalenyl)ethyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-98-5 CAPLUS
CN Urea, N-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)-N'-(5-[[(1-tricyclo[3.3.1.13,7]dec-1-ylethyl)amino]methyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A



RN 322689-99-6 CAPLUS
CN Urea, N-[5-[[[2-(1H-indol-3-yl)-1-methylethyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
a]isoindol-10-yl)- (9CI) (CA INDEX NAME)



RN 322690-04-0 CAPLUS
CN Urea, N-[5-[[(5-bromo-2,3-dihydro-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(3,4,6,10b-tetrahydro-2-methyl-6-oxo-2H-[1,3]oxazino[2,3-a]isoindol-10-yl)- (9CI) (CA INDEX NAME)



IT **322688-42-6P 322688-43-7P 322689-12-3P**
322689-14-5P 322689-16-7P 322689-17-8P
322689-31-6P 322689-32-7P 322689-33-8P
322689-37-2P 322689-38-3P 322689-39-4P
322689-44-1P 322689-45-2P 322726-83-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 322690-00-6 CAPLUS
CN Urea, N-[5-[[[(1R)-1-methyl-3-phenylpropyl]amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322690-01-7 CAPLUS
CN Urea, N-[5-[[(2-methoxy-1-methylethyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322690-03-9 CAPLUS
CN Urea, N-[5-[[(5-bromo-2,3-dihydro-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(3,4,6,10b-tetrahydro-2,3-dimethyl-6-oxo-2H-[1,3]oxazino[2,3-

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(prepn. of N-(hetero)aryl-N'-heterocyclylurea derivs. as inhibitors of cyclin-dependent kinases (Cdk4 and Cdk6) and antitumor agents)
RN 322688-42-6 CAPLUS
CN Urea, N-[5-[(4-methyl-1-piperazinyl)methyl]-1H-pyrazol-3-yl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322688-43-7 CAPLUS
CN Urea, N-[5-[(4-methyl-1-piperazinyl)methyl]-1H-pyrazol-3-yl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322689-12-3 CAPLUS
CN Urea, N-[5-[(2S)-1-(phenylmethyl)-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-14-5 CAPLUS
CN Urea, N-[5-[(2S)-1-(phenylmethyl)-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322689-16-7 CAPLUS
CN Urea, N-[5-[(2R)-1-(phenylmethyl)-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-17-8 CAPLUS
CN Urea, N-[5-[(2R)-1-(phenylmethyl)-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322689-31-6 CAPLUS
CN Urea, N-(5-cyclopentyl-1H-pyrazol-3-yl)-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-32-7 CAPLUS
CN Urea, N-(5-cyclopentyl-1H-pyrazol-3-yl)-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322689-33-8 CAPLUS
CN Urea, N-[5-[(2S,4R)-4-(phenylmethoxy)-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-37-2 CAPLUS
CN Urea, N-[5-[(3R)-5-oxo-1-(phenylmethyl)-3-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322689-38-3 CAPLUS
CN Urea, N-[5-[(3S)-5-oxo-1-(phenylmethyl)-3-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-39-4 CAPLUS
CN Urea, N-[5-[(3R)-5-oxo-1-(phenylmethyl)-3-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322689-44-1 CAPLUS
CN Urea, N-[5-[(2S)-1-formyl-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-45-2 CAPLUS
CN Urea, N-[5-[(2S)-1-formyl-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322726-83-0 CAPLUS
CN Urea, N-[5-[(2S,4R)-4-(phenylmethoxy)-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **322681-94-7P 322683-91-0P 322688-41-5P**
322688-44-8P 322688-45-9P 322688-46-0P
322688-47-1P 322689-18-9P 322689-19-0P
322689-23-6P 322689-24-7P 322689-25-8P
322689-26-9P 322689-27-0P 322689-48-5P
322690-02-8P 322692-20-6P 322692-31-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(hetero)aryl-N'-heterocyclylurea derivs. as inhibitors of
cyclin-dependent kinases (Cdk4 and Cdk6) and antitumor agents)

RN 322681-94-7 CAPLUS
CN Urea, N-(9-oxo-9H-fluoren-4-yl)-N'-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 322683-91-0 CAPLUS
CN Urea, N-(5-phenyl-1H-pyrazol-3-yl)-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-41-5 CAPLUS
CN Urea, N-[5-(hydroxymethyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-44-8 CAPLUS
CN Urea, N-[5-[[(1-ethylpropyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-45-9 CAPLUS
CN Urea, N-[5-[[(2-methylpropyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322688-46-0 CAPLUS
CN Urea, N-[5-[[(2,2-dimethylpropyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-19-0 CAPLUS
CN Urea, N-[5-(2-naphthalenyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-23-6 CAPLUS
CN Urea, N-[5-(2S)-2-pyrrolidinyl-1H-pyrazol-3-yl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322688-47-1 CAPLUS
CN Urea, N-[5-[[(1,1-dimethylpropyl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 322689-18-9 CAPLUS
CN Urea, N-[5-(2-methylphenyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-24-7 CAPLUS
CN Urea, N-[5-(2S)-2-pyrrolidinyl-1H-pyrazol-3-yl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322689-25-8 CAPLUS
CN Urea, N-[5-(2R)-2-pyrrolidinyl-1H-pyrazol-3-yl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-26-9 CAPLUS
CN Urea, N-[5-(2R)-2-pyrrolidinyl-1H-pyrazol-3-yl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322689-27-0 CAPLUS
CN Urea, N-[5-(2-pyridinyl)-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322689-48-5 CAPLUS
CN Urea, N-[5-[1-(butylamino)ethyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 322690-02-8 CAPLUS
CN Urea, N-[5-[[(5-bromo-2,3-dihydro-1H-inden-2-yl)amino]methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-2,3-dimethyl-5-oxooxazolo[2,3-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322692-20-6 CAPLUS
CN Urea, N-[5-[(4-methyl-1-piperazinyl)methyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A



RN 322692-31-9 CAPLUS
CN Urea, N-[5-[(2S)-1-methyl-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **322692-24-0P 322693-26-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-(hetero)aryl-N'-heterocyclylurea derivs. as inhibitors of cyclin-dependent kinases (Cdk4 and Cdk6) and antitumor agents)

RN 322692-24-0 CAPLUS
CN Urea, N-[5-[(2S)-1-(phenylmethyl)-2-pyrrolidinyl]-1H-pyrazol-3-yl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 322693-26-5 CAPLUS
CN Urea, N-(5-formyl-1H-pyrazol-3-yl)-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 23 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:824211 CAPLUS
DOCUMENT NUMBER: 134:4764
TITLE: Preparation of 3-(benzoylamino)propionic acid derivatives as glucagon antagonists/inverse agonists
INVENTOR(S): Ling, Anthony; Plewe, Michael Bruno; Truesdale, Larry Kenneth; Lau, Jesper; Madsen, Peter; Sams, Christian; Behrens, Carsten; Vagner, Josef; Christensen, Inge Thoger; Lundt, Behrend Frederik; Sidelmann, Ulla Grove; Thogersen, Henning
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; Agouron Pharmaceuticals, Inc.
SOURCE: PCT Int. Appl., 564 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069810	A1	20001123	WO 2000-DK264	20000516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6503949	B1	20000516	US 2000-572553	20000516
EP 1183229	A1	20020306	EP 2000-926725	20000516
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000010651	A	20020319	BR 2000-10651	20000516
JP 2002544254	T2	20021224	JP 2000-618228	20000516
ZA 2001008560	A	20020613	ZA 2001-8560	20011018
NO 2001005607	A	20020117	NO 2001-5607	20011116
US 2003220350	A1	20031127	US 2002-233851	20020830

PRIORITY APPLN. INFO.:

DK 1999-684	A	19990517
DK 2000-478	A	20000321
US 1999-134415P	P	19990517
US 2000-191685P	P	20000323
US 2000-572553	A3	20000516
WO 2000-DK264	W	20000516

OTHER SOURCE(S): MARPAT 134:4764
GI

L6 ANSWER 23 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

II



III

AB The title compds. [I; V = CO2R2, CONR2R3, CONR2OR3, etc. (wherein R2, R3 = H, alkyl); A = (CH2)n(CR8R9)bNR7, (CR8R9)b(CH2)nNR7, (CR8R9)b(CH2)n, etc. (b = 0-1; n = 0-3; R7 = H, alkyl, (cycloalkyl)alkyl; R8, R9 = H, alkyl); Y = CO, SO2, O, a bond; Z = (un)substituted phenylene, divalent radical derived from 5-6 membered heteroarom. ring containing 1-2 heteroatoms selected from N, O and S; or AYZ together = II; R1 = H, alkyl; X = CO(CR13R14)r(CH2)s, SO2(CR13R14)r(CH2)s, CO2(CR13R14)r(CH2)s, etc. (r = 0-1; s = 0-3; R13, R14 = H, alkyl); D = (un)substituted Ph, pyridyl, cyclopropyl, etc.; E = (un)substituted quinolinyl, 2,5-dioxopiperidinyl, biphenylalkyl, etc.] which act to antagonize the action of the glucagon hormone on the glucagon receptor (data given), and therefore may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity, were prepared and formulated. E.g., a multi-step solid phase synthesis of III was given. Compds. I are effective at 0.05-10 mg/kg/day.

IT **307985-04-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(benzoylamino)propionic acid derivs. as glucagon antagonists/inverse agonists)

RN 307985-04-2 CAPLUS
CN β-Alanine, N-[4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][[(5-phenyl-1H-pyrazol-3-yl)amino]carbonyl]amino]methyl]benzoyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L6 ANSWER 23 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 24 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:619239 CAPLUS
DOCUMENT NUMBER: 133:344173
TITLE: 1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors
AUTHOR(S): Dumas, J.; Hatoum-Mokdad, H.; Sibley, R.; Riedl, B.; Scott, W. J.; Monahan, M. K.; Lowinger, T. B.; Brennan, C.; Natero, R.; Turner, T.; Johnson, J. S.; Schoenleber, R.; Bhargava, A.; Wilhelm, S. M.; Housley, T. J.; Ranges, G. E.; Shrikhande, A.
CORPORATE SOURCE: Department of Chemistry Research, Bayer Research Center, West Haven, CT, 06516, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(18), 2051-2054
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Inhibitors of the MAP kinase p38 are potentially useful for the treatment of arthritis and osteoporosis. Several 2,3-dichlorophenyl ureas were identified as small-mol. inhibitors of p38 by a combinatorial chemical effort. Optimization for cellular potency led to the discovery of a new class of potent and selective p38 kinase inhibitors, exemplified by the 1-phenyl-5-pyrazolyl urea 7 (IC50=13 nM).

IT **229001-84-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(1-Phenyl-5-pyrazolyl ureas: preparation and inhibition of p38 kinase in relation to structure)

RN 229001-84-7 CAPLUS
CN Urea, N-(2,3-dichlorophenyl)-N'-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 25 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:335409 CAPLUS
DOCUMENT NUMBER: 132:334474
TITLE: Preparation of spiroindolines as Y5 receptor antagonists
INVENTOR(S): Gao, Ying-duo; Macneil, Douglas J.; Yang, Lihu; Morin, Nancy R.; Fukami, Takehiro; Kanatani, Akio; Fukuroda, Takahiro; Ishii, Yasuyuki; Morin, Masaki
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Banyu Pharmaceutical Co., Ltd.; et al.
SOURCE: PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027845	A1	20000518	WO 1999-US26447	19991108
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6191160	B1	20010220	US 1999-436120	19991108
EP 1129089	A1	20010905	EP 1999-971808	19991108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 756797	B2	20030123	AU 2000-14732	19991108
US 6313298	B1	20011106	US 2000-656698	20000907
US 2002058813	A1	20020516	US 2001-896940	20010629
US 6495559	B2	20021217		
US 6638942	B1	20031028	US 2002-228250	20020826
US 2004063942	A1	20040401	US 2003-624414	20030721

PRIORITY APPLN. INFO.:
US 1998-107835P P 19981110
US 1999-436120 A3 19991108
WO 1999-US26447 W 19991108
US 2000-656698 A3 20000907
US 2001-896940 A3 20010629
US 2002-228250 A3 20020826

OTHER SOURCE(S): MARPAT 132:334474
GI

L6 ANSWER 25 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB The title compds. I [V, W, X, Z = CH, N; R1 = H, alkyl, etc.; R2 = CHO, etc.; R3 = H, alkyl; Ar = aryl, heteroaryl; R4, R5 = H, nitro, etc.] are prepared I are useful in the treatment of obesity and the complications associated therewith. 1-Methanesulfonyl-N-(5-phenyl-2-pyrazinyl)spiro[indoline-3,4'-piperidine]-1'-carboxamide at 3 mg/kg suppressed bovine pancreatic polypeptide-induced food intake in rats. Formulations are given.

IT **268537-08-2P 268537-09-3P 268537-11-7P**
268537-13-9P 268537-16-2P 268537-33-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of spiroindolines as Y5 receptor antagonists)

RN 268537-08-2 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxamide, N-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1,2-dihydro-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 25 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

RN 268537-09-3 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxamide, 1,2-dihydro-N-[5-(5-methoxy-3-pyridinyl)-1H-pyrazol-3-yl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 268537-11-7 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxamide, 1,2-dihydro-N-[5-(3-methoxyphenyl)-1H-pyrazol-3-yl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 25 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 268537-13-9 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxamide, N-[5-(3-chlorophenyl)-1H-pyrazol-3-yl]-1,2-dihydro-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 25 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 268537-16-2 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxamide, 1,2-dihydro-1-(methylsulfonyl)-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 25 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 268537-33-3 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxamide, N-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-(ethylsulfonyl)-1,2-dihydro- (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 25 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 26 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:314688 CAPLUS
DOCUMENT NUMBER: 132:334455
TITLE: 2-Ureidothiazole derivatives, process for their preparation, and their use as antitumor agents
INVENTOR(S): Pevarello, Paolo; Amici, Raffaella; Traquandi, Gabriella; Villa, Manuela; Vulpetti, Anna; Isacchi, Antonella
PATENT ASSIGNEE(S): Pharmacia & Upjohn S.p.A., Italy
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000026203	A1	20000511	WO 1999-EP8307	19991027
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 9914868	A	20010703	BR 1999-14868	19991027
EP 1124811	A1	20010822	EP 1999-953959	19991027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002528538	T2	20020903	JP 2000-579592	19991027
NZ 510967	A	20031031	NZ 1999-510967	19991027
AU 771166	B2	20040318	AU 2000-10447	19991027
ZA 2001002869	A	20011010	ZA 2001-2869	20010406
NO 2001002058	A	20010628	NO 2001-2058	20010426
US 2003187040	A1	20031002	US 2001-830668	20010430
US 2004157827	A1	20040812	US 2004-770019	20040202

PRIORITY APPLN. INFO.: GB 1998-23873 A 19981030
WO 1999-EP8307 W 19991027
US 2001-830668 A1 20010430

OTHER SOURCE(S): MARPAT 132:334455
GI



I

AB The title 2-ureido-1,3-thiazole derivs. I and their pharmaceutically acceptable salts are disclosed [wherein R = halo, nitro, (un)substituted amino, C1-6 alkyl, C3-6 cycloalkyl, aryl, or arylalkyl; R1 = (un)substituted C1-6 alkyl, 3- to 6-membered carbocycle or 5- to 7-membered heterocycle, aryl, arylcarbonyl, or arylalkyl; R2 = H, straight

L6 ANSWER 26 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
or branched C1-4 alkyl, C2-4 alkenyl, or alkynyl; or NR1R2 = (un)substituted, optionally benzo-condensed or bridged 5- to 7-membered heterocycle, or 9- to 11-membered spiro-heterocycle]. The compds. are active as cdk/cyclin inhibitors, and are useful for treating cell proliferative disorders assocd. with an altered cell dependent kinase activity. The proliferative disorders include cancer and a wide variety of other conditions, such as Alzheimer's disease, viral infections, autoimmune diseases, and neurodegenerative disorders. Over 230 invention compds. are claimed and/or prepd. in examples. For instance, reaction of Ph isocyanate with 2-amino-5-bromo-1,3-thiazole hydrobromide in the presence of Et3N gave title compd. I [R = Br, R1 = Ph, R2 = H]. The similarly prepd. title compd. I [R = iso-Pr, R1 = 3,5-dimethylphenyl, R2 = H] inhibited cdk2/cyclin A complex in vitro with an IC50 of 0.56 μM.

IT **267432-17-7P 267432-18-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of ureidothiazole derivs. as antitumor agents)

RN 267432-17-7 CAPLUS
CN Urea, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-N'-[5-(1-methylethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 267432-18-8 CAPLUS
CN Urea, N-[5-(1-methylethyl)-2-thiazolyl]-N'-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 27 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:425745 CAPLUS
DOCUMENT NUMBER: 131:87909
TITLE: Inhibition of p38 kinase activity using substituted heterocyclic ureas
INVENTOR(S): Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Paulsen, Holger; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee, Wendy; Redman, Aniko
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932111	A1	19990701	WO 1998-US26080	19981222
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2315720	AA	19990701	CA 1998-2315720	19981222
AU 9919971	A1	19990712	AU 1999-19971	19981222
AU 739642	B2	20011018		
EP 1041982	A1	20001011	EP 1998-964709	19981222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001526223	T2	20011218	JP 2000-525102	19981222

PRIORITY APPLN. INFO.: US 1997-995750 A 19971222
WO 1998-US26080 W 19981222

OTHER SOURCE(S): MARPAT 131:87909
GI



II

AB A method for treatment of p38-mediated disease other than cancer comprises administration of ANHCONHB [I; A = substituted isoxazolyl, pyrazolyl, thienyl, furyl; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl containing ≥1 5-6 membered aromatic structure containing 0-4 N, O, or S atoms]. Reaction of 4-(4-pyridinylthio)aniline with 3-tert-butyl-5-isoxazolyl isocyanate in toluene gave title compound II. In an in vitro p38 kinase assay, I displayed IC50 values of 1-10 μM.

L6 ANSWER 27 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

IT **229001-78-9P 229001-83-6P 229001-84-7P**
229001-85-8P 229001-86-9P 229001-87-0P
229001-89-2P 229001-90-5P 229001-91-6P
229001-92-7P 229002-92-0P 229155-37-7P
229155-72-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heterocyclic ureas for treatment of p38 kinase-mediated diseases other than cancer)

RN 229001-78-9 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-[4-(4-methoxyphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 229001-83-6 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 229001-84-7 CAPLUS
CN Urea, N-(2,3-dichlorophenyl)-N'-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 229001-85-8 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-[4-(4-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 27 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 229001-86-9 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-[3-(4-pyridinylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 229001-87-0 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-[4-(4-pyridinylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 229001-89-2 CAPLUS
CN Benzamide, 3-[4-[[[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]carbonyl]amino]phenoxy]-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 229001-88-1
CMF C22 H25 N5 O3

L6 ANSWER 27 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 229002-92-0 CAPLUS
CN Urea, N-(3,4-dichlorophenyl)-N'-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 229155-37-7 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 229155-72-0 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-[3-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 27 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 229001-90-5 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 229001-91-6 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-[4-(4-methylphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 229001-92-7 CAPLUS
CN Urea, N-[3-(2-benzothiazolyloxy)phenyl]-N'-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

L6 ANSWER 28 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:425740 CAPLUS
DOCUMENT NUMBER: 131:73648
TITLE: Inhibition of raf kinase using substituted heterocyclic ureas
INVENTOR(S): Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Paulsen, Holger; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee, Wendy; Redman, Aniko
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932106	A1	19990701	WO 1998-US26078	19981222
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2315717	AA	19990701	CA 1998-2315717	19981222
AU 9921989	A1	19990712	AU 1999-21989	19981222
EP 1047418	A1	20001102	EP 1998-965981	19981222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200002618	T2	20010420	TR 2000-200002618	19981222
JP 2001526220	T2	20011218	JP 2000-525097	19981222
BR 9814374	A	20020514	BR 1998-14374	19981222
RU 2232015	C2	20040710	RU 2000-120184	19981222
NO 2000003232	A	20000821	NO 2000-3232	20000621
BG 104597	A	20010228	BG 2000-104597	20000712

PRIORITY APPLN. INFO.: US 1997-996343 A 19971222
WO 1998-US26078 W 19981222

OTHER SOURCE(S): MARPAT 131:73648
GI



II

AB A method for treatment of cancerous cell growth mediated by raf kinase comprises administration of urea derivs. ANHCONHB [I; A = substituted isoxazolyl, thienyl, thiadiazolyl, furyl, pyrazolyl, etc.; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl containing ≥1 5-6 membered aromatic structure containing 0-4 N, O, or S atoms]. Reaction of

L6 ANSWER 28 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
4-phenyloxyphenyl isocyanate with 5-amino-3-tert-butylisoxazole in methylene chloride and heating at reflux temp. for 2 days gave title compd. II. In an in vitro raf kinase assay, I displayed IC50 values of 1-10 μM.

IT **229001-77-8P 229001-78-9P 229001-79-0P**
229001-80-3P 229001-81-4P 229001-82-5P
229001-83-6P 229001-84-7P 229001-85-8P
229001-86-9P 229001-87-0P 229001-89-2P
229001-90-5P 229001-91-6P 229001-92-7P
229002-78-2P 229002-92-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heterocyclic ureas for treatment of cancerous cell growth mediated by raf kinase)

RN 229001-77-8 CAPLUS
CN Urea, N-(4-(4-acetylphenoxy)phenyl]-N'-(5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 229001-78-9 CAPLUS
CN Urea, N-(5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-[4-(4-methoxyphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 229001-79-0 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-[4-(3-methylphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 229001-80-3 CAPLUS

L6 ANSWER 28 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 229001-85-8 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-[4-(4-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 229001-86-9 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-[3-(4-pyridinylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 229001-87-0 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-[4-(4-pyridinylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 229001-89-2 CAPLUS
CN Benzamide, 3-[4-[[[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]carbonyl]amino]phenoxy]-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 229001-88-1

L6 ANSWER 28 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-[4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 229001-81-4 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-[6-[(4-methoxyphenyl)thio]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 229001-82-5 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-[4-(4-fluorophenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 229001-83-6 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 229001-84-7 CAPLUS
CN Urea, N-(2,3-dichlorophenyl)-N'-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

L6 ANSWER 28 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CMF C22 H25 N5 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 229001-90-5 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 229001-91-6 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N'-[4-(4-methylphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 229001-92-7 CAPLUS
CN Urea, N-[3-(2-benzothiazolyloxy)phenyl]-N'-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

L6 ANSWER 28 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 229002-78-2 CAPLUS
CN Urea, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-N'-[6-[4-[(trifluoromethyl)thio]phenoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 229002-92-0 CAPLUS
CN Urea, N-(3,4-dichlorophenyl)-N'-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

L6 ANSWER 28 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 29 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:375437 CAPLUS
DOCUMENT NUMBER: 131:27961
TITLE: Hypolipemic agents
INVENTOR(S): Fukami, Takehiro; Fukuroda, Takahiro; Kanatani, Akio; Ihara, Masaki
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 171 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9927965	A1	19990610	WO 1998-JP5358	19981127
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9912621	A1	19990616	AU 1999-12621	19981127
PRIORITY APPLN. INFO.:			JP 1997-344357	19971128
			JP 1998-169216	19980602
			WO 1998-JP5358	19981127

GI



AB Remedies for hypercholesterolemia, hyperlipemia and arteriosclerosis containing as the active ingredient neuropeptide Y Y5 receptor antagonists typified by, for example, a compound represented by formula [I]. Formulation examples of I were given.

IT **208518-75-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(neuropeptide Y Y5 receptor antagonists as hypolipemic and antiatherosclerotic agents)

RN 208518-75-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 29 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 30 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:126025 CAPLUS
DOCUMENT NUMBER: 130:311726
TITLE: Acyl derivatives of 3-(p-aminophenyl)-5-aminopyrazole and its N(1)-substituted derivatives
AUTHOR(S): Nam, N. L.; Grandberg, I. I.; Sorokin, V. I.
CORPORATE SOURCE: Timiryazevsk. Sel'skokhoz. Akad., Russia
SOURCE: Izvestiya Timiryazevskoi Sel'skokhozyaistvennoi Akademii (1998), (3), 201-211
CODEN: ITSAA7; ISSN: 0021-342X
PUBLISHER: Izdatel'stvo MSKhA
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 130:311726
GI



I

AB Title compds. such as I (R = H, Me, Ph, o-tolyl, p-tolyl) were acylated on both primary amino groups.
IT **223518-44-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 223518-44-3 CAPLUS
CN Benzenesulfonamide, 2-chloro-N-[[[5-[4-[[[[(2-chlorophenyl)sulfonyl]amino]carbonyl]amino]phenyl]-1H-pyrazol-3-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 30 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L6 ANSWER 31 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:394327 CAPLUS
DOCUMENT NUMBER: 129:54391
TITLE: Preparation of urea moiety-containing pyrazole derivatives as neuropeptide Y antagonists
INVENTOR(S): Fukami, Takehiro; Fukuroda, Takahiro; Kanatani, Akio; Ihara, Masaki
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9824768	A1	19980611	WO 1997-JP4399	19971202
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9851359	A1	19980629	AU 1998-51359	19971202
EP 955293	A1	19991110	EP 1997-946071	19971202
EP 955293	B1	20030319		
R: DE, FR, GB, IT				
US 6043246	A	20000328	US 1999-308668	19990726
PRIORITY APPLN. INFO.:			JP 1996-337593 A	19961203
			WO 1997-JP4399 W	19971202

OTHER SOURCE(S): MARPAT 129:54391
GI



I

AB The title compds. I [A represents nitrogen or a group represented by CR5; Ar1 represents aryl optionally having substituent(s) selected from the group consisting of halogeno, lower alkyl, and lower haloalkyl; Ar2 represents aryl or heteroaryl optionally having substituent(s) selected from the group consisting of halogeno, lower alkyl, lower alkenyl, lower haloalkyl, lower alkoxy, lower alkylthio, lower alkylamino, lower dialkylamino, and aryl; R1 represents hydrogen or lower alkyl or is bonded to R5 to represent a bond; R2 represents hydrogen or lower alkyl; R3 and R4 are the same or different and each represents hydrogen or lower alkyl, or R3 and R4 are bonded to each other to represent C2-4 alkylene optionally having lower alkyl; and R5 represents hydrogen, hydroxy, lower alkyl, or lower alkoxy or is bonded to R1 to represent a bond] are prepared I are useful in the treatment of hyperphagia, obesity, or diabetes. In an in vitro test for neuropeptide Y antagonism, 3-[4-(3-chlorophenyl)piperazinyl]carbonylamino-5-(4-methoxyphenyl)pyrazole showed

L6 ANSWER 31 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
IC50 of 27 nM.
IT **208518-75-6P 208518-76-7P 208518-77-8P**
208518-78-9P 208518-79-0P 208518-80-3P
208518-81-4P 208518-82-5P 208518-83-6P
208518-84-7P 208518-85-8P 208518-86-9P
208518-87-0P 208518-88-1P 208518-89-2P
208518-90-5P 208518-91-6P 208518-92-7P
208518-93-8P 208518-94-9P 208518-95-0P
208518-96-1P 208518-97-2P 208518-98-3P
208518-99-4P 208519-00-0P 208519-01-1P
208519-02-2P 208519-03-3P 208519-04-4P
208519-05-5P 208519-06-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of urea moiety-containing pyrazole derivs. as neuropeptide Y antagonists)
RN 208518-75-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 208518-76-7 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 208518-77-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-(2-methylphenyl)-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 31 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 208518-78-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-(3-methylphenyl)-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 208518-79-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-(4-methylphenyl)-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 208518-80-3 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-(2-methoxyphenyl)-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 31 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 208518-81-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-(3,4-dichlorophenyl)-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 208518-82-5 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-(4-bromophenyl)-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 208518-83-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-(3-chlorophenyl)-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 31 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 208518-84-7 CAPLUS
CN 1-Piperazinecarboxamide, 4-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 208518-85-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-[4-(dimethylamino)phenyl]-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 208518-86-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-[3-(dimethylamino)phenyl]-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 31 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 208518-87-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 208518-88-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-[4-(1-methylethoxy)phenyl]-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 208518-89-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-(4-ethoxyphenyl)-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 31 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 208518-90-5 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-(3-bromophenyl)-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 208518-91-6 CAPLUS
CN 1-Piperazinecarboxamide, 4-(3-chlorophenyl)-N-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 208518-92-7 CAPLUS
CN 1-Piperazinecarboxamide, 4-(3-chlorophenyl)-N-[5-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

L6 ANSWER 31 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 208518-96-1 CAPLUS
CN 1-Piperazinecarboxamide, 4-phenyl-N-[5-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 208518-97-2 CAPLUS
CN Urea, N'-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-N-methyl-N-[2-[(2-methylphenyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 208518-98-3 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-(3-methoxyphenyl)-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 31 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 208518-93-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-(2-chlorophenyl)-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 208518-94-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-[4-(methylthio)phenyl]-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 208518-95-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-(1,3-benzodioxol-5-yl)-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 31 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 208518-99-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 208519-00-0 CAPLUS
CN Urea, N-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-N'-[2-(phenylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 208519-01-1 CAPLUS
CN 1-Piperazinecarboxamide, N-(5-[1,1'-biphenyl]-4-yl-1H-pyrazol-3-yl)-4-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 31 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 208519-02-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-[3-(dimethylamino)-4-methoxyphenyl]-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 208519-03-3 CAPLUS
CN 1-Piperazinecarboxamide, 4-(4-hydroxyphenyl)-N-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 208519-04-4 CAPLUS
CN 1(2H)-Pyridinecarboxamide, 3,6-dihydro-N-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 31 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 208519-05-5 CAPLUS
CN 1-Piperidinecarboxamide, N-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 208519-06-6 CAPLUS
CN 1H-1,4-Diazepine-1-carboxamide, hexahydro-N-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-4-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 32 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:531751 CAPLUS
DOCUMENT NUMBER: 127:220346
TITLE: Gas-phase pyrolysis in heterocyclic synthesis. Gas-phase elimination reactions of some substituted aminoazoles
AUTHOR(S): Al-Awadi, Nouria A.; Elnagdi, Mohamed H.
CORPORATE SOURCE: Chemistry Department, Kuwait University, Safat, 13060, Kuwait
SOURCE: Heteroatom Chemistry (1997), 8(4), 293-297
CODEN: HETCE8; ISSN: 1042-7163
PUBLISHER: Wiley
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Gas-phase pyrolyzes of Et N-(5-cyanomethyl-1,3,4-thiadiazol-3-yl)carbamate, 1-benzoyl-3-(3-methylpyrazol-5-yl)thiourea, 1-benzoyl-3-(5-methylisoxazol-3-yl)thiourea and 1-acetyl-3-(3-phenylpyrazol-5-yl)thiourea were studied. These reactions were homogeneous and unimol., and their kinetics obeyed the 1st-order rate equation. Using this pyrolytic reaction in heterocyclic synthesis is considered, and mechanistic information was obtained from kinetic data and product anal. using an online pyrolysis/GC-MS technique. The phys. consts. of 4 new substituted aminoazoles are also described.
IT **195048-73-8**
RL: PEP (Physical, engineering or chemical process); PRP (Properties); RCT (Reactant); PROC (Process); RACT (Reactant or reagent)
(kinetics and mechanism of thermal elimination reactions of some substituted aminoazoles and gas-phase pyrolysis in heterocyclic synthesis)
RN 195048-73-8 CAPLUS
CN Ethanethioamide, N-[[(5-phenyl-1H-pyrazol-3-yl)amino]carbonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 33 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1993:2383 CAPLUS
DOCUMENT NUMBER: 118:2383
TITLE: Growth regulatory effects of heterocyclic derivatives of p-toluene- and p-chlorobenzene-sulfonylurea on plant seeds
AUTHOR(S): Kato, Motoyasu; Obara, Yoshihiko; Murata, Michio
CORPORATE SOURCE: Agr. Coll., Meijo Univ., Nagoya, Japan
SOURCE: Meijo Daigaku Nogakubu Gakujutsu Hokoku (1992), 28, 49-59
CODEN: MDNGBZ; ISSN: 0910-3376
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
AB The plant growth regulatory activities of some sulfonylurea compds., having a 4-substituted group in the aryl moiety, on 4 kinds of plants were evaluated using a germination test. Sixty new p-toluenesulfonylurea and 8 new p-chlorobenzenesulfonylurea derivs. were synthesized from p-toluene or p-chlorobenzenesulfonylisocyanate and from heterocyclic amines. According to the method of G. Levitt (1981). Relatively pure compds. were obtained without any special purification techniques, and were subjected directly to the biol. activity tests. The p-toluenesulfonylurea derivs. were tested at the concns. of 500 ppm. The test revealed that many pyridine and pyrimidine derivs. had strong inhibitory activities. Most hetero-pentacyclic derivs. exhibited no inhibitory activity. Some compds. promoted roots. The compds. with the promotive activities were among the hetero-pentacyclic derivs. Some p-toluenesulfonylurea compds. and new p-chlorobenzenesulfonylureas, which had the same heterocyclic skeleton, were also examined at the concns. of 20, 100 and 500 ppm. Some p-toluenesulfonylureas and p-chlorobenzenesulfonylurea showed potent inhibitory activities on the roots and shoots of lettuce.
IT **144849-11-6P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and plant growth regulating activity of, concentration in relation to)
RN 144849-11-6 CAPLUS
CN Benzenesulfonamide, 4-methyl-N-[[(5-methyl-1H-pyrazol-3-yl)amino]carbonyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 34 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1983:594955 CAPLUS
DOCUMENT NUMBER: 99:194955
TITLE: Pyrazole derivatives and herbicidal compositions containing them
INVENTOR(S): Seki, Nansho; Yamaguchi, Yuki; Nakamura, Yukihiro; Kubo, Hiroshi; Tsuruya, Tetsuo
PATENT ASSIGNEE(S): Showa Denko K. K. , Japan
SOURCE: Ger. Offen., 37 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3305483	A1	19830825	DE 1983-3305483	19830217
JP 58144372	A2	19830827	JP 1982-23668	19820218
JP 03036833	B4	19910603		
JP 58144373	A2	19830827	JP 1982-23669	19820218
JP 03071424	B4	19911113		
JP 59084871	A2	19840516	JP 1982-194592	19821108
CH 653998	A	19860131	CH 1983-827	19830215
CA 1194884	A1	19851008	CA 1983-421704	19830216
FR 2521557	A1	19830819	FR 1983-2669	19830218
AU 8311650	A1	19830825	AU 1983-11650	19830218
AU 547406	B2	19851017		
GB 2115416	A1	19830907	GB 1983-4627	19830218
GB 2115416	B2	19860305		
US 4501606	A	19850226	US 1983-467630	19830218
PRIORITY APPLN. INFO.:			JP 1982-23668	19820218
			JP 1982-23669	19820218
			JP 1982-194592	19821108

OTHER SOURCE(S): CASREACT 99:194955
GI



I

AB Herbicidal pyrazoles I (R = H, Br, Cl; R1 = alkoxy, alkenyloxy, amino) (16 compds.) were prepared Thus, 125 g Me3CCOCH2CN was cyclocondensed with 55 g N2H4.H2O to give 131 g 3-amino-5-tert-butyl-1H-pyrazole. This (42 g) was acylated with 34 g ClCO2Me to give 44 g I (R = H, R1 = OMe) (II). In pre- and post-emergence tests, 10 kg II/ha gave complete kill of, e.g. Digitaria sanguinalis.
IT **87844-81-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and herbicidal activity of)

L6 ANSWER 34 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 87844-81-3 CAPLUS
CN Urea, N'-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N,N-diethyl- (9CI) (CA INDEX NAME)



IT **87844-78-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, bromination, chlorination, and herbicidal activity of)
RN 87844-78-8 CAPLUS
CN Urea, N'-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



L6 ANSWER 35 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1975:443280 CAPLUS
DOCUMENT NUMBER: 83:43280
TITLE: New synthesis of pyrazolo[1,5-a]-s-triazines
AUTHOR(S): Vogel, Arnold; Troxler, Franz
CORPORATE SOURCE: Pharm.-Dep., Sandoz A.-G., Basel, Switz.
SOURCE: Helvetica Chimica Acta (1975), 58(3), 761-71
CODEN: HCACAV; ISSN: 0018-019X
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 83:43280
GI For diagram(s), see printed CA Issue.
AB Pyrazolo[1,5-a]-s-triazines I and I (R1 = H, Me, R2 = Me, PhNH, MeO, HO HS; R3 = H, CHO) were prepared by addition of AcNCO to 5-amino-3-methylpyrazole
followed by hydrolysis to give N-(3-methyl-5-pyrazolyl)urea which cyclized with MeC(OEt)3 or by condensation of aminoguanidine with β-oxonitriles to give 1-amidino-5-aminopyrazole which was cyclized by reaction with orthoesters, mixed anhydrides, isocyanides, or carbonyldiimidazole derivs. Reaction of 4-aminopyrazolo[1,5-a]-s-triazines with electrophiles gave substitution at position 8.
IT **56130-87-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cycloaddn. reaction of, with orthoacetic acid ester)
RN 56130-87-1 CAPLUS
CN Urea, (5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



IT **56130-86-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deacetylation of)
RN 56130-86-0 CAPLUS
CN Acetamide, N-[[(5-methyl-1H-pyrazol-3-yl)amino]carbonyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 36 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1967:10875 CAPLUS
DOCUMENT NUMBER: 66:10875
TITLE: Pyrazole derivatives. III
AUTHOR(S): Dymek, Wojciech; Janik, Boleslaw; Ryznerski, Zygmunt
CORPORATE SOURCE: Akad. Med., Cracow, Pol.
SOURCE: Acta Poloniae Pharmaceutica (1966), 23(3), 207-14
CODEN: APPHAX; ISSN: 0001-6837
DOCUMENT TYPE: Journal
LANGUAGE: Polish
GI For diagram(s), see printed CA Issue.
AB cf. CA 63, 18066h. Several derivs. of 3-(p-chlorophenyl)pyrazole were synthesized for antibacterial screening. p-ClC6H4COCH2CN and 2.5 moles 80% N2H4.H2O heated 1 hr. on a water bath yielded I (R = H), m. 170-1° (H2O); hydrochloride m. 225-7° (EtOH-C6H6); picrate m. 199-200° (EtOH). The following I were prepared by 2-hr. heating of I (R = H) with 1 mole acyl chloride in C5H5N or 1 mole isocyanate in EtOH (R and m.p. given): Ac, 182-4° (EtOH); Bz, 257-8° (EtOH); p-AcNHC6H4SO2, 260-1° (Me2CO-C6H6); p-H2NC6H4SO2, 263-4° (Me2CO-C6H6); PhNCO, 139-40° (dilute EtOH); 1-C10H7NHCO, 255-6° (PhMe). I (R = H) in EtOH refluxed 1 hr. with 1 mole appropriate aldehyde yielded II (R = m.p. given): o-O2NC6H4, 206-7° (EtOH); PhCH:CH, 216° (C6H6); o-HOC6H4, 229-30° (C6H6). I (R = H) heated 3 hrs. with 1 mole α-oxo ester in EtOH gave III (R = Me), m. 341° (PhMe), and III (R = Ph), m. 340° (PhMe). I (R = H) heated 1.5 hrs. with 1 mole isothiocyanate in EtOH yielded IV (R and m.p. given): Me, 221-2° (EtOH); Et, 214° (dilute EtOH); CH2:CHCH2, 201-2° (dilute EtOH); Ph, 199-200° and 220° (EtOH); o-MeC6H4, 205-6° and 223-4° (EtOH).
IT **13097-23-9P 13097-24-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 13097-23-9 CAPLUS
CN Urea, 1-[5-(p-chlorophenyl)pyrazol-3-yl]-3-phenyl- (8CI) (CA INDEX NAME)



RN 13097-24-0 CAPLUS
CN Urea, 1-[5-(p-chlorophenyl)pyrazol-3-yl]-3-(1-naphthyl)- (8CI) (CA INDEX NAME)

L6 ANSWER 36 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L6 ANSWER 37 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1965:498286 CAPLUS
DOCUMENT NUMBER: 63:98286
ORIGINAL REFERENCE NO.: 63:18066h,18067a-c
TITLE: Pyrazole derivatives. II
AUTHOR(S): Dymek, Wojciech; Janik, Boleslaw; Zimon, Romuald
CORPORATE SOURCE: Akad. Med., Cracow
SOURCE: Acta Polon. Pharm. (1965), 22(3), 209-17
DOCUMENT TYPE: Journal
LANGUAGE: Polish

GI For diagram(s), see printed CA Issue.

AB cf. CA 62, 10428a. Certain reactions of 3-(p-bromophenyl)-5-aminopyrazole (I) were studied. I heated 1 hr. at 100° with 1 mole acyl chloride (II) in C5H5N yielded III (R : H) (R1 and m.p. given): Bz, 266-7° (EtOH); AcO, 191-2° (PhMe); p-AcNHC6H4SO2, 264° (aqueous EtOH); p-H2NC6HS4O2, 272-3° (aqueous EtOH). When II was used in excess, the following III were obtained (R : R1 and m.p. given): Ac, 192° (aqueous EtOH); ClCH2CO, 198-200° (C6H6). I treated similarly with isocyanates yielded III (R : H) (R1 and m.p. given): PhNHCO, 279-81° (ligroine); α-C10H7NHCO, 255-7° (PhMe). I heated 1 hr. in absolute EtOH with aldehydes yielded Schiff bases IV (aldehyde component and m.p. given): o02NC6H4CHO, 213-16° (EtOH); 4-formyl-5-methyl-2-phenyl-3-pyrazolone, 296-7° (dioxane); o-HOC6H4CHO, 235-7° (C6H6); PhCH:CHCHO, 221-2° (C6H6). I heated 1 hr. at 150° with 1 mole AcCH2CO2Et or BzCH2CO2Et yielded V (R and m.p. given); Me, 345-7° (EtOH); Ph, 351° (AcOH). I refluxed 90 min. with 1 mole isothiocyanate in EtOH yielded VI (R and m.p. given): Me, 236-7° (EtOH); Et, 232-4.5° (PhMe); allyl, 202-3° (aqueous EtOH); Ph, 204-6° (244-5°) (EtOH); o-MeC6H4, 215-16° (250-1°) (EtOH). I, m. 175-6° (H2O), was prepared in 95% yield by refluxing equimolar amts. of 80% (NH2)2.H2O and p-BrC6H4COCH2CN in EtOH 4 hrs.; I hydrochloride m. 219-21° (EtOH), and I picrate m. 198° (EtOH)

IT **97441-18-4**, Urea, 1-[5(or 3)-(p-bromophenyl)pyrazol-3(or 5)yl]-3-phenyl- **100027-16-5**, Urea, 1-[5(or 3)-(p-bromophenyl)pyrazol-3(or 5)yl]-3-(1-naphthyl)-
(preparation of)

RN 97441-18-4 CAPLUS

CN Urea, 1-[5(or 3)-(p-bromophenyl)pyrazol-3(or 5)-yl]-3-phenyl- (7CI) (CA INDEX NAME)



RN 100027-16-5 CAPLUS

CN Urea, 1-[5(or 3)-(p-bromophenyl)pyrazol-3(or 5)-yl]-3-(1-naphthyl)- (7CI) (CA INDEX NAME)

L6 ANSWER 37 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L6 ANSWER 38 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1965:58907 CAPLUS
DOCUMENT NUMBER: 62:58907
ORIGINAL REFERENCE NO.: 62:10428a-d
TITLE: Pyrazole derivatives. I
AUTHOR(S): Dymek, Wojciech; Janik, Boleslaw; Samson, Oktawian
CORPORATE SOURCE: Akad. Med. Krakow
SOURCE: Acta Polon. Pharm. (1964), 21(2), 211-16
DOCUMENT TYPE: Journal
LANGUAGE: Polish

GI For diagram(s), see printed CA Issue.

AB 3-Phenyl-5-(p-acetamido-phenylsulfonamido)pyrazole (I), m. 119-20°, was obtained by refluxing equimol. amts. of 3-phenyl-5-aminopyrazole (II), p-acetamidobenzenesulfonyl chloride (III), and pyridine in anhydrous CHCl3 for 1 hr. Refluxing I in 2N NaOH for 2 hrs. yielded 3-phenyl-5-(p-aminophenylsulfonamido)pyrazole, m. 241-2°. 3-Phenyl-4-bromo-5-aminopyrazole-HBr (IV), m. 222-3°, was obtained by adding dropwise, at room temperature, 0.02 moles Br to 0.01 mole II in CHCl3; the free base m. 92-3°. Heating equimolar amts. of III, IV, and pyridine in CHCl3 for 1 hr. on a water bath yielded 3-phenyl-4-bromo-5-(p-acetamidophenylsulfonamido)pyrazole, which refluxed 1 hr. in 2N NaOH yielded 3-phenyl-4-bromo-5-(p-aminophenylsulfonamido)pyrazole, m. 213-14°. 3-Phenyl-5-chloroacetylaminopyrazole, m. 249-50°, was obtained by heating for 1 hr. 1.6 g. II in pyridine with 1.2 g. chloroacetic acid. N-(3-Phenyl-5-pyrazolyl)-N'-phenylurea (m. 154-5°), N-(3-phenyl-5-pyrazolyl)-N'-β-naphthylurea [m. 297.5-300° (decomposition)], and the α-naphthyl analog (m. 150-2°) were obtained by heating for 1 hr. 1.6 g. II in EtOH with 1.2 g. Ph,β-naphthyl, or α-naphthyl isocyanate, resp. Heating equimolar amts. II and isocyanates in EtOH for 1 hr. yielded the following V (R and m.p. given): Me, 219-21°; Et, 207-9° CH2CH:CH2, 186-8°; Ph, 191-2°; o-MeC6H4, 209-11°. The activity of the compds. against Toxoplasma gondii was studied.

IT **97953-41-8**, Urea, 1-phenyl-3-[5(or 3)-phenylpyrazol-3(or 5)yl]- **100546-05-2**, Urea, 1-(2-naphthyl)-3-[5(or 3)-phenylpyrazol-3(or 5)-yl]- **100546-06-3**, Urea, 1-(1-naphthyl)-3-[5(or 3)-phenylpyrazol-3(or 5)-yl]-
(preparation of)

RN 97953-41-8 CAPLUS

CN Urea, 1-phenyl-3-[5(or 3)-phenylpyrazol-3(or 5)-yl]- (7CI) (CA INDEX NAME)



RN 100546-05-2 CAPLUS

CN Urea, 1-(2-naphthyl)-3-[5(or 3)-phenylpyrazol-3(or 5)-yl]- (7CI) (CA INDEX NAME)

L6 ANSWER 38 OF 38 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 100546-06-3 CAPLUS
CN Urea, 1-(1-naphthyl)-3-[5(or 3)-phenylpyrazol-3(or 5)-yl]- (7CI) (CA INDEX NAME)



=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	186.16	367.46

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-26.60	-26.60

FILE 'REGISTRY' ENTERED AT 10:53:25 ON 20 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 AUG 2004 HIGHEST RN 728239-10-9
DICTIONARY FILE UPDATES: 18 AUG 2004 HIGHEST RN 728239-10-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> S 256529-50-7/RN

L7 1 256529-50-7/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L7 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y
THE ESTIMATED COST FOR THIS REQUEST IS 5.92 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L7 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **256529-50-7** REGISTRY
CN Urea, N-ethyl-N'-[5-[4-phenyl-5-(trifluoromethyl)-2-thienyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H15 F3 N4 O S
SR CAS Client Services



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=>

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.19	369.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-26.60

FILE 'REGISTRY' ENTERED AT 10:53:56 ON 20 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 AUG 2004 HIGHEST RN 728239-10-9
DICTIONARY FILE UPDATES: 18 AUG 2004 HIGHEST RN 728239-10-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> S 256529-50-7/RN

L8 1 256529-50-7/RN

=> FIL CHEMCATS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	370.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-26.60

FILE 'CHEMCATS' ENTERED AT 10:53:58 ON 20 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE LAST UPDATED 14 AUGUST 2004 (20040814UP)

For details on recent updates in CHEMCATS, enter NEWS FILE at an arrow prompt. For the list of suppliers currently in the file, enter HELP SPA, HELP SPBC, HELP SPDH, HELP SPIN, HELP SPOP, and HELP SPQZ. For the list of current catalogs, enter HELP CTA, HELP CTBC, HELP CTDH, HELP CTIN, HELP CTOP, and HELP CTQZ.

This database is provided on an "as is" basis. Please consult the suppliers for current information regarding pricing, regional availability, available quantities, purities, etc. THERE ARE NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. ACS is not liable for any loss of profit, goodwill or any other damages arising out of the use of this database.

CHEMCATS now contains more than 6 million records. See HELP CONTENT and NEWS FILE for details.

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> SET LIN 80

SET COMMAND COMPLETED

=> S L8

L9 0 L8

=> D ALL 1-

L9 HAS NO ANSWERS
L8 1 SEA FILE=REGISTRY ABB=ON PLU=ON 256529-50-7/RN
L9 0 SEA FILE=CHEMCATS ABB=ON PLU=ON L8

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=>

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.85	370.92

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-26.60

FILE 'REGISTRY' ENTERED AT 10:54:14 ON 20 AUG 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 AUG 2004 HIGHEST RN 728239-10-9
DICTIONARY FILE UPDATES: 18 AUG 2004 HIGHEST RN 728239-10-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> S 256529-50-7/RN

L10 1 256529-50-7/RN

=> FIL CHEMCATS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	371.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-26.60

FILE 'CHEMCATS' ENTERED AT 10:54:16 ON 20 AUG 2004

FILE LAST UPDATED 14 AUGUST 2004 (20040814UP)

For details on recent updates in CHEMCATS, enter NEWS FILE at an arrow prompt. For the list of suppliers currently in the file, enter HELP SPA, HELP SPBC, HELP SPDH, HELP SPIN, HELP SPOP, and HELP SPQZ. For the list of current catalogs, enter HELP CTA, HELP CTBC, HELP CTDH, HELP CTIN, HELP CTOP, and HELP CTQZ.

This database is provided on an "as is" basis. Please consult the suppliers for current information regarding pricing, regional availability, available quantities, purities, etc. THERE ARE NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. ACS is not liable for any loss of profit, goodwill or any other damages arising

out of the use of this database.

CHEMCATS now contains more than 6 million records. See HELP CONTENT and NEWS FILE for details.

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> SET LIN 80

SET COMMAND COMPLETED

=> S L10

L11 0 L10

=> D RN CN PRICE COMP 1-

L11 HAS NO ANSWERS
L10 1 SEA FILE=REGISTRY ABB=ON PLU=ON 256529-50-7/RN
L11 0 SEA FILE=CHEMCATS ABB=ON PLU=ON L10

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=>

=> log y
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.90	383.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-26.60

STN INTERNATIONAL LOGOFF AT 11:02:46 ON 20 AUG 2004